<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOXIFLOXACINÂ - moxifloxacin hydrochlorideÂ injection, solutionÂ </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MOXIFLOXACIN safely and effectively. See full prescribing information forÂ MOXIFLOXACIN.<br><br>MOXIFLOXACINÂ Injection, forÂ intravenous use<br>Initial U.S. Approval: 1999<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin injection and other antibacterial drugs, moxifloxacin injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: TENDON EFFECTS and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing Information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including moxifloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. Â This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Â </span><span class="Bold">Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs <span class="Italics">(<a href="#b861fd0b-b607-412e-8efa-1132ded74bac">5.1</a>)</span>.<span class="Italics"></span></span> </p>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including moxifloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Â Avoid moxifloxacin in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">(<a href="#fb741801-c7e6-4034-8fbf-b7bcb62a456c">5.2</a>)</span>.</span>Â  </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: TENDON EFFECTS and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing Information for complete boxed warning</span></span></h1>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including moxifloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages. Â This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Â </span><span class="Bold">Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs <span class="Italics">(<a href="#b861fd0b-b607-412e-8efa-1132ded74bac">5.1</a>)</span>.<span class="Italics"></span></span> </p>
<p class="Highlighta"><span class="Bold">Fluoroquinolones, including moxifloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. Â Avoid moxifloxacin in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">(<a href="#fb741801-c7e6-4034-8fbf-b7bcb62a456c">5.2</a>)</span>.</span>Â  </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Moxifloxacin injection is a fluoroquinolone antibacterial drug indicated for treating <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults â‰¥ 18 years of age caused by designated, susceptible bacteria. (<a href="#d5a8a8f2-ceec-4f1c-abd1-a905a051b4b2">1</a>, <a href="#fbbcd44d-654a-4262-8938-7d30eb8f8439">12.4</a>) </p>
<ul class="Disc">
<li>Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (<a href="#a5b484b4-edc4-4f96-b83a-024a7226062d">1.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (<a href="#eb0d35fa-dd76-4e07-a1c9-c806c0736994">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> (<a href="#ae0cff90-de19-4b7a-99ae-ecaf62a2cad2">1.3</a>)</li>
<li>Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: Uncomplicated (<a href="#fba7814d-6334-4df9-ac48-eee361afeab8">1.4</a>) and Complicated (<a href="#f72c4aa5-744a-46da-9a98-7e4212fb0e5e">1.5</a>)</li>
<li>Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> (<a href="#acd52fde-3de3-48ba-94c5-697b09158c10">1.6</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br><span class="Bold">Dose Every 24 hours </span><br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br><span class="Bold">Duration (days) </span><br>Â <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (<a href="#a5b484b4-edc4-4f96-b83a-024a7226062d">1.1</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>10 <br>Â <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (<a href="#eb0d35fa-dd76-4e07-a1c9-c806c0736994">1.2</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>5 <br>Â <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> (<a href="#ae0cff90-de19-4b7a-99ae-ecaf62a2cad2">1.3</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>7 to 14 <br>Â <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) (<a href="#fba7814d-6334-4df9-ac48-eee361afeab8">1.4</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>7 <br>Â <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Complicated SSSI (<a href="#f72c4aa5-744a-46da-9a98-7e4212fb0e5e">1.5</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>7 to 21 <br>Â <br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> (<a href="#acd52fde-3de3-48ba-94c5-697b09158c10">1.6</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>400 mg <br>Â <br><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>5 to 14 <br>Â <br><br>
</td>
</tr>
</tbody></table>
<ul class="Disc">
<li>No dosage adjustment in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#fb827024-b656-435c-870c-e9f046833ca6">8.6</a>, <a href="#a25bf694-51f7-452d-8e63-09d248f822f5">8.7</a>)</li>
<li>Moxifloxacin injection: SlowÂ Intravenous infusion over 60 minutes. Â Avoid rapid or bolus Intravenous infusion. (<a href="#efcbe6ef-0080-4b4c-bc17-4d41947cb068">2.2</a>)</li>
<li>Do not mix with other medications in intravenous bag or in intravenous line. (<a href="#efcbe6ef-0080-4b4c-bc17-4d41947cb068">2.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Injection:Â  400 mg moxifloxacinÂ in 250 mL. (<a href="#c04d7cdf-eb26-4de1-8205-1d61d7c1a776">3.1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to moxifloxacin or other quinolones. (<a href="#a9564560-fc40-4666-8299-794367b19a48">4</a>, <a href="#ad2aac79-831c-437d-a963-2de34c131b15">5.4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Prolongation of the QT interval and isolated cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> has been reported. Â Avoid use in patients with known prolongation, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and with drugs that prolong the QT interval. (<a href="#dda9bc24-2e4e-44b1-acc7-4a5afd6c7c7b">5.3</a>, <a href="#b5fef2b1-28d9-46d4-9a63-9ccb14236f30">7.4</a>, <a href="#ec3c1ed1-ba91-4d8a-9989-e2e4535b616d">8.5</a>). Â Use caution in patients with proarrhythmic conditions such as clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>. (<a href="#dda9bc24-2e4e-44b1-acc7-4a5afd6c7c7b">5.3</a>)</li>
<li>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, may occur after first or subsequent doses. Â Discontinue drug use at first sign of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. (<a href="#ad2aac79-831c-437d-a963-2de34c131b15">5.4</a>, <a href="#f56b5077-167f-4f0a-a943-5e0ee31d1fa1">5.5</a>)</li>
<li>Central nervous system (CNS) events including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, andÂ suicidal thoughts or acts may occur after first dose. Â Use caution in patients with known or suspected CNS disorders that may predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#df54d2ec-ec5a-4505-bc0c-d1fe5e8b12db">5.6</a>)</li>
<li>
<span class="Italics"><span class="Italics">Clostridium difficile</span></span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#cba97293-10fc-44bd-aa19-427e7f27c7ad">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>: Discontinue if symptoms occur. (<a href="#c9530bc3-9982-4d0a-b5a3-a6a2ba013635">5.8</a>)</li>
<li>High sodium load: each unit dose contains 52.5 mEq (1207 mg) of sodium.Â  Avoid in patients with sodium restriction. (<a href="#ad76dfb6-3a54-48d3-9b49-14f2924e3125.13">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common reactions (â‰¥ 3%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. (<a href="#aac6189f-2b66-43ac-a564-ad47d8459735">6.2</a>) </p>
<p class="Highlighta"><span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance &amp; Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Interacting Drug </span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Interaction </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Warfarin <br>
</td>
<td class="Rrule" valign="top">Anticoagulant effect of warfarin may be enhanced. Â Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR, watch for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#b9f9984e-b2f5-4ca2-a502-6aabe8057ff4">6.4</a>, <a href="#f6b1f349-54cb-40fd-ada5-5c67b4185bdb">7.1</a>, <a href="#f9b0e307-baa4-4303-aa02-5a9aa970ac1b">12.3</a>) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Class IA and Class III antiarrhythmics: <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmic effect</span> may be enhanced. Avoid concomitant use. (<a href="#dda9bc24-2e4e-44b1-acc7-4a5afd6c7c7b">5.3</a>, <a href="#b5fef2b1-28d9-46d4-9a63-9ccb14236f30">7.4</a>) <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Antidiabetic agentsÂ </td>
<td class="Rrule" valign="top">Carefully monitor blood glucose. (<a href="#ad76dfb6-3a54-48d3-9b49-14f2924e3125.12">5.11</a>, <a href="#da3cb6c7-4e7e-4b78-b2d8-710680e32514.6">7.2</a>)Â </td>
</tr>
</tbody></table></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Pregnancy:<span class="Italics">Â </span></span>Based on animal data may cause fetal harm. (<a href="#c512a5b7-9945-46c5-b077-59de2e47c37f">8.1</a>)</li>
<li>
<span class="Bold">Geriatrics: </span>Increased risk for severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval. (<a href="#b861fd0b-b607-412e-8efa-1132ded74bac">5.1</a>, <a href="#dda9bc24-2e4e-44b1-acc7-4a5afd6c7c7b">5.3</a>, <a href="#ec3c1ed1-ba91-4d8a-9989-e2e4535b616d">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: TENDON EFFECTS and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Administration Instructions</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Preparation for Administration of Moxifloxacin Injection</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 QT Prolongation</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Other Serious and Sometimes Fatal Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Central Nervous System Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Clostridium Difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 High Sodium Load</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Arthropathic Effects in Animals</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Blood Glucose Disturbances</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Development of Drug Resistant Bacteria</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Serious and Otherwise Important Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Laboratory Changes</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Warfarin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Antidiabetic Agents</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs that Prolong QT</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Caused by Multi-Drug Resistant Streptococcus pneumoniae (MDRSP)</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: TENDON EFFECTS and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">MYASTHENIA GRAVIS</span></h1>
<p class="First"><span class="Bold">Fluoroquinolones, including moxifloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages.Â  This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.Â Â </span><span class="Bold">Discontinue if <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in a tendon occurs</span><span class="Bold">Â <span class="Italics">[seeÂ <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]. <br><br></span></span><span class="Bold">Fluoroquinolones, including moxifloxacin, may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.Â  Avoid moxifloxacin in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[seeÂ <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin injection<span class="Sup">Â </span>and other antibacterial drugs, moxifloxacin injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.Â  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.Â  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. </p>
<p>Moxifloxacin injection is indicated for the treatment of adults (18 years of age or older) with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible isolates of the designated microorganisms in the conditions listed below <span class="Italics">[seeÂ <a href="#Section_2">Dosage and Administration (2)</a>Â andÂ <a href="#Section_8.5">Use in Specific Populations (8.5)</a>]. </span></p>
<br><p><span class="Bold">Culture and Susceptibility Testing </span></p>
<p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and to determine their susceptibility to moxifloxacin <span class="Italics">[seeÂ <a href="#Section_12.4">Clinical Pharmacology (12.4)</a>]</span>. Â Therapy with moxifloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. </p>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae</span>, or <span class="Italics">Moraxella catarrhalis </span><span class="Italics">[seeÂ <a href="#Section_14.4">Clinical Studies (14.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> caused by <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae,</span> methicillin-susceptible <span class="Italics">Staphylococcus aureus,</span> or <span class="Italics">Moraxella catarrhalis [seeÂ <a href="#Section_14.1">Clinical Studies (14.1</a>)]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> caused by <span class="Italics">Streptococcus pneumoniae</span> (including multi-drug resistant isolates*), <span class="Italics">Haemophilus influenzae, Moraxella catarrhalis,</span> methicillin-susceptible <span class="Italics">Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae,</span> or <span class="Italics">Chlamydophila pneumoniae</span>.Â <br><br>* MDRSP, Multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin (<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> [MIC] â‰¥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole <span class="Italics">[seeÂ <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by methicillin-susceptible <span class="Italics">Staphylococcus aureus</span> or <span class="Italics">Streptococcus pyogenes</span>Â <span class="Italics">[seeÂ <a href="#Section_14.5">Clinical Studies (14.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by methicillin-susceptible <span class="Italics">Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae,</span> or <span class="Italics">Enterobacter cloacae</span>Â <span class="Italics">[see </span><span class="Italics"><a href="#Section_14.6">Clinical Studies (14.6)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></h2>
<p class="First">Moxifloxacin is indicated for the treatment of Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> including polymicrobial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> caused by <span class="Italics">Escherichia coli, Bacteroides fragilis, Streptococcus anginosus,</span>Â <span class="Italics">Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron,</span> or <span class="Italics">Peptostreptococcus</span> species <span class="Italics">[seeÂ <a href="#Section_14.7">Clinical Studies (14.7</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in Adult Patients</h2>
<p class="First">The dose of moxifloxacin injection is 400 mg intravenously once every 24 hours.Â  The duration of therapy depends on the type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> as described in Table 1.Â Â Â </p>
<br><p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Table 1: Dosage and Duration of Therapy in Adult Patients</span>Â </p>
<table border="0" cellpadding="0" cellspacing="0" width="582"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Â </span><br><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span><span class="Bold"><span class="Sup">a</span></span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dose Every 24 hours</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Duration</span><span class="Bold"><span class="Sup">b</span></span><span class="Bold"> (days)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (<a href="#Section_1.1">1.1</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span> (<a href="#Section_1.2">1.2</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (SSSI) (<a href="#Section_1.4">1.4</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Complicated SSSI (<a href="#Section_1.5">1.5</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 21<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> (<a href="#Section_1.6">1.6</a>) <br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">5 to 14<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Due to the designatedÂ pathogens <span class="Italics">[seeÂ <a href="#Section_1">Indications and Usage (1)</a>,</span> for IV use, seeÂ <span class="Italics"><span class="Italics"><a href="#Section_8.5">Use in Specific Populations (8.5)</a></span>].Â </span></p>
<br><p><span class="Sup">b</span> Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician.<br></p>
<br><br><p>When switching from intravenous to oral formulation, no dosage adjustment is necessary <span class="Italics">[see <span class="Italics"><a href="#Section_12.4">Clinical Pharmacology (12.4)</a></span>]</span>.Â  Patients whose therapy is started with moxifloxacin injection may be switched to moxifloxacin tablets when clinically indicated at the discretion of the physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Administration Instructions</h2>
<p class="First"><span class="Italics">Moxifloxacin Injection Solution for Infusion </span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. </p>
<p>Moxifloxacin injection should be administered by intravenous infusion only.Â  It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration. </p>
<p>Moxifloxacin injection should be administered by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place.Â  Caution: rapid or bolus intravenous infusion must be avoided. </p>
<p>Because only limited data are available on the compatibility of moxifloxacin intravenous injection with other intravenous substances, additives or other medications should not be added to moxifloxacin injection or infused simultaneously through the same intravenous line.Â  If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the â€œpiggybackâ€? method of administration is used, the line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> before and after infusion of moxifloxacin injection with an infusion solution compatible with moxifloxacin injection as well as with other drug(s) administered via this common line. </p>
<p><span class="Bold">Moxifloxacin Injection is compatible with the following intravenous solutions at ratios from 1:10 to 10:1 </span></p>
<p>0.9% Sodium Chloride Injection, USP Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Sterile Water for Injection, USP </p>
<p>1 molar Sodium Chloride InjectionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10% Dextrose for Injection, USP </p>
<p>5% Dextrose Injection, USPÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Lactated Ringerâ€™s for Injection</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Preparation for Administration of Moxifloxacin Injection</h2>
<p class="First">To prepare moxifloxacin injection premix in flexible plastic containers: </p>
<p>1.Â  Close flow control clamp of administration set. </p>
<p>2.Â  Remove cover from port at bottom of container. </p>
<p>3.Â  Insert piercing pin from an appropriate transfer set (for example, one that does not require excessive force,Â such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated. </p>
<br><p><span class="Bold">NOTE:</span> Refer to complete directions that have been provided with the administration set.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold"><span class="Underline">Moxifloxacin Injection </span></span></p>
<p>Each bag contains 400 mg of moxifloxacin in 250 mL, each mL contains 1.6 mg of moxifloxacin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Moxifloxacin is contraindicated in persons with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to moxifloxacin or any member of the quinolone class of antimicrobial agents.Â </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span></h2>
<p class="First">Fluoroquinolones, including moxifloxacin, are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in all ages.Â  This adverse reaction most frequently involves the Achilles tendon, and rupture of the Achilles tendon may require surgical repair.Â  <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> in the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites have also been reported.Â  The risk of developing fluoroquinolone-associated <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.Â  Factors, in addition to age and corticosteroid use, that may independently increase the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> include strenuous physical activity, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and previous <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.Â  <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> have also occurred in patients taking fluoroquinolones who do not have the above risk factors.Â  <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported.Â  Moxifloxacin should be discontinued if the patient experiences <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or rupture of a tendon.Â  Patients should be advised to rest at the first sign of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_6.4">Adverse Reactions (6.4)</a></span>Â <span class="Italics">and</span>Â <span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></h2>
<p class="First">Fluoroquinolones, including moxifloxacin, have neuromuscular blocking activity and may exacerbate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.Â  Postmarketing serious adverse events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and requirement for ventilatory support, have been associated with fluoroquinolone use in persons with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.Â  Avoid moxifloxacin in patients with known history of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> <span class="Italics">[seeÂ <a href="#Section_17">Patient Counseling Information (17)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 QT Prolongation</h2>
<p class="First">Moxifloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients. Â Following oral dosing with 400 mg of moxifloxacin the mean (Â± SD) change in QTc from the pre-dose value at the time of maximum drug concentration was 6 msec (Â± 26) (n = 787). Â Following a course of daily intravenous dosing (400 mg; 1 hour infusion each day) the mean change in QTc from the Day 1 pre-dose value was 10 msec (Â± 22) on Day 1 (n = 667) and 7 msec (Â± 24) on Day 3 (n = 667). Â </p>
<p>The drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and patients receiving Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations. </p>
<p>Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. Â An additive effect of moxifloxacin and these drugs cannot be excluded; therefore caution should be exercised when moxifloxacin is given concurrently with these drugs. Â In premarketing clinical trials, the rate of cardiovascular adverse events was similar in 798 moxifloxacin and 702 comparator treated patients who received concomitant therapy with drugs known to prolong the QTc interval. </p>
<p>Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>. Â The magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing rates of infusion of the intravenous formulation. Â Therefore the recommended dose or infusion rate should not be exceeded. Â QT prolongation may lead to an increased risk for <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. Â No excess in cardiovascular morbidity or mortality attributable to QTc prolongation occurred with moxifloxacin treatment in over 15,500 patients in controlled clinical studies, including 759 patients who were hypokalemic at the start of treatment, and there was no increase in mortality in over 18,000 moxifloxacin tablet treated patients in a postmarketing observational study in which ECGs were not performed. Â Elderly patients using moxifloxacin injection may be more susceptible to drug-associated QT prolongation <span class="Italics">[seeÂ <a href="#Section_8.5">Use in Specific Populations (8.5)</a>]. Â </span>In addition, moxifloxacin should be used with caution in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span> <span class="Italics">[see</span>Â <span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span><span class="Italics"> andÂ </span><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, some following the first dose, have been reported in patients receiving quinolone therapy, including moxifloxacin.Â  Some reactions were accompanied by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.Â  Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine.Â  Moxifloxacin should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.Â  Oxygen, intravenous steroids, and airway management, including intubation, may be administered as indicated <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_6">Adverse Reactions (6)</a></span>Â <span class="Italics">and </span><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Other Serious and Sometimes Fatal Reactions</h2>
<p class="First">Other serious and sometimes fatal events, some due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with quinolones, including moxifloxacin.Â  These events may be severe and generally occur following the administration of multiple doses.Â  Clinical manifestations may include one or more of the following: </p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or severe dermatologic reactions (for example, toxic epidermalÂ Â  necrolysis, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) </p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> </p>
<p>â€¢ Allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> </p>
<p>â€¢ Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal insufficiency</span> or failure </p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> or failure </p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including hemolytic and aplastic; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, including thromboticÂ Â  <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; and/or other hematologic abnormalities </p>
<p>The drug should be discontinued immediately at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and supportive measures instituted <span class="Italics">[seeÂ <a href="#Section_17">Patient Counseling Information (17)</a> andÂ <a href="#Section_6.4">Adverse Reactions (6.4)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Central Nervous System Effects</h2>
<p class="First">Fluoroquinolones, including moxifloxacin, may cause central nervous system (CNS) events, including: <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> or <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span> <span class="Italics">[seeÂ <a href="#Section_6.2">Adverse ReactionsÂ (6.2,</a><a href="#Section_6.4">6.4)</a>]</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> (including <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) have been reported in patients receiving fluoroquinolones.Â  Fluoroquinolones may also cause central nervous system (CNS) events including: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and, rarely, suicidal thoughts or acts.Â  These reactions may occur following the first dose.Â  If these reactions occur in patients receiving moxifloxacin, the drug should be discontinued and appropriate measures instituted.Â  As with all fluoroquinolones, moxifloxacin should be used with caution in patients with known or suspected CNS disorders (for example, severe <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) or in the presence of other risk factors that may predispose to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold <span class="Italics">[see </span><span class="Italics"><a href="#Section_7.3">Drug Interactions (7.3)</a></span><span class="Italics">,Â </span><span class="Italics"><a href="#Section_6.2">Adverse Reactions (6.2,</a></span><span class="Italics"></span><span class="Italics"><a href="#Section_6.4">6.4</a></span><span class="Italics">)</span>Â <span class="Italics">andÂ </span><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Clostridium Difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including moxifloxacin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.Â  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.Â Â </p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.Â  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.Â  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.Â  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.Â Â </p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued.Â  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated <span class="Italics">[seeÂ <a href="#Section_6.2">Adverse Reactions (6.2)</a>andÂ <a href="#Section_17">Patient Counseling Information (17)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<p class="First">Cases of sensory or sensorimotor axonal <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> affecting small and/or large axons resulting in <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesias</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> have been reported in patients receiving fluoroquinolones including moxifloxacin.Â  Symptoms may occur soon after initiation of moxifloxacin and may be irreversible.Â  Moxifloxacin should be discontinued immediately if the patient experiences symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or other alterations of sensation including light touch, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, temperature, position sense, and vibratory sensation <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_6">Adverse Reactions</a></span>Â <span class="Italics">(</span><span class="Italics"><a href="#Section_6.2">6.2</a></span><span class="Italics">,Â </span><span class="Italics"><a href="#Section_6.4">6.4</a></span><span class="Italics">) and </span><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 High Sodium Load</h2>
<p class="First">Each unit dose of moxifloxacin injection contains 52.5 mEq (1,207 mg) of sodium. Avoid use of moxifloxacin injection in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, elderly, and those with restricted sodium intake<span class="Italics"> [seeÂ <a href="#Section_8.5">Use in</a>Â <a href="#Section_8.5">Specific Populations (8.5)</a>,Â <a href="#Section_11">Description (11)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Arthropathic Effects in Animals</h2>
<p class="First">The oral administration of moxifloxacin caused lameness in immature dogs.Â  Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage.Â  Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals of various species <span class="Italics">[seeÂ <a href="#Section_13.2">Nonclinical Toxicology (13.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Blood Glucose Disturbances</h2>
<p class="First">As with all fluoroquinolones, disturbances in blood glucose, including both <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported with moxifloxacin.Â  In moxifloxacin-treated patients, dysglycemia occurred predominantly in elderly diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (for example, sulfonylurea) or with insulin.Â  In diabetic patients, careful monitoring of blood glucose is recommended <span class="Italics">[seeÂ </span><a href="#Section_6.2">Adverse Reactions (6.2)] .</a>Â  If a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs, moxifloxacin should be discontinued and appropriate therapy should be initiated immediately <span class="Italics">[seeÂ <a href="#Section_6.2">Adverse Reactions (6.2)</a> andÂ <a href="#Section_17">Patient Counseling Information (17)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span></h2>
<p class="First">Moderate to severe <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reactions, the latter of which may manifest as exaggerated sunburn reactions (for example, burning, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, exudation, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) involving areas exposed to light (typically the face, â€œVâ€? area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolone antibiotics after sun or UV light exposure.Â  Therefore, excessive exposure to these sources of light should be avoided.Â  Drug therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> occurs <span class="Italics">[seeÂ <a href="#Section_6.4">Adverse Reactions (6.4)</a> andÂ <a href="#Section_12.3">Clinical PharmacologyÂ (12.3)]</a></span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Development of Drug Resistant Bacteria</h2>
<p class="First">Prescribing moxifloxacin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria <span class="Italics">[seeÂ <a href="#Section_17">Patient Counseling Information (17)]</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Serious and Otherwise Important Adverse Reactions</h2>
<p class="First">The following serious and otherwise important adverse reactions are discussed in greater detail in the Warnings and Precautions section of the label: </p>
<p>â€¢Â  Tendinopathy and <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon Rupture</span> <span class="Italics">[seeÂ <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span></p>
<p>â€¢Â  QT Prolongation <span class="Italics">[seeÂ <a href="#Section_5.3">Warnings and Precautions (5.3)]</a></span></p>
<p>â€¢Â  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[seeÂ <a href="#Section_5.4">Warnings and Precautions (5.4)</a>]</span></p>
<p>â€¢Â  Other Serious and Sometimes Fatal Reactions <span class="Italics">[seeÂ <a href="#Section_5.5">Warnings and Precautions (5.5)</a>]</span></p>
<p>â€¢Â  Central Nervous System Effects <span class="Italics">[seeÂ <a href="#Section_5.6">Warnings and Precautions (5.6)]</a></span></p>
<p>â€¢Â  <span class="Italics">Clostridium Difficile</span>-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <span class="Italics">[seeÂ <a href="#Section_5.7">Warnings and Precautions (5.7)</a>]</span></p>
<p>â€¢Â  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span> that may be irreversible <span class="Italics">[seeÂ  <a href="#Section_5.8">Warnings and Precautions (5.8)]</a></span></p>
<p>â€¢Â  Blood Glucose Disturbances <span class="Italics">[seeÂ <a href="#Section_5.11">Warnings and Precautions (5.11)</a>]</span></p>
<p>â€¢Â  <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span> <span class="Italics">[seeÂ <a href="#Section_5.12">Warnings and Precautions (5.12)</a>]</span></p>
<p>Â â€¢Â  Development of Drug Resistant Bacteria <span class="Italics">[seeÂ <a href="#Section_5.13">Warnings and Precautions (5.13)</a>]</span>Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Â Â </p>
<p>The data described below reflect exposure to moxifloxacin in 14,981 patients in 71 active controlled Phase II - IV clinical trials in different indications <span class="Italics">[see</span>Â <span class="Italics"><a href="#Section_1">Indications and Usage (1)]</a></span>. Â The population studied had a mean age of 50 years (approximately 73% of the population was &lt; 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Â Patients received moxifloxacin 400 mg once daily PO, IV, or sequentially (IV followed by PO). Â Treatment duration was usually 6 to 10 days, and the mean number of days on therapy was 9 days.Â </p>
<p>Discontinuation of moxifloxacin due to adverse events occurred in 5% of patients overall, 4.1% of patients treated with 400 mg PO, 3.9% with 400 mg IV and 8.2% with sequential therapy 400 mg PO/IV. Â The most common adverse events leading to discontinuation with the 400 mg PO doses were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.8%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (0.5%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (0.4%). Â The most common adverse event leading to discontinuation with the 400 mg IV dose was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.5%). Â The most common adverse events leading to discontinuation with the 400 mg IV/PO sequential dose were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.5%) and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (0.4%).</p>
<p>Adverse reactions occurring in â‰¥ 1% of moxifloxacin-treated patients and less common adverse reactions, occurring in 0.1 to &lt; 1% of moxifloxacin-treated patients, are shown in Table 2 and Table 3, respectively. Â The most common adverse drug reactions (â‰¥ 3%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. </p>
<br><p><span class="Bold">Table 2: Common (â‰¥ 1%) Adverse Reactions Reported in Active-Controlled </span><span class="Bold">Clinical Trials with Moxifloxacin</span>Â </p>
<table border="0" cellpadding="0" cellspacing="0" width="690">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">
<span class="Bold">System Organ Class </span><br>
</th>
<th class="Lrule Rrule Toprule">
<span class="Bold">Adverse Reactions<span class="Sup">a</span></span><span class="Bold"></span><br>
</th>
<th class="Lrule Rrule Toprule" align="center">
<span class="Bold">% (N=14,981) </span><br>
</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Blood and Lymphatic System Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.1 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="7" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">6.9<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Rrule" align="center" valign="top">2.4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>
</td>
<td class="Rrule" align="center" valign="top">1.9 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">1.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span><br>
</td>
<td class="Rrule" align="center" valign="top">1.1 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">General Disorders and Administration Site Conditions </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.1 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Investigations </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased <br>
</td>
<td class="Rrule" align="center" valign="top">1.1 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Metabolism and Nutritional Disorder </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> <br>
</td>
<td class="Rrule" align="center" valign="top">4.2<br>3<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Psychiatric Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1.9 <br>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>MedDRA Version 12.0 </p>
<br><br><p><span class="Bold">Table 3: Less Common (0.1 to &lt; 1%) Adverse Reactions Reported in Active-Controlled </span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Clinical Trials with Moxifloxacin (N=14,981)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="661">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">
<span class="Bold">System Organ Class </span><br>
</th>
<th class="Lrule Rrule Toprule">
<span class="Bold">Adverse Reactions<span class="Sup">a</span></span><span class="Bold"></span><br>
</th>
<th class="Lrule Rrule Toprule">Â <br>
</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="6" valign="top">
<span class="Bold">Blood and Lymphatic System Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="8" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac failure congestive</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">
<span class="Bold">Ear and Labyrinth Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="6" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span> <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span><br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="11" valign="top">
<span class="Bold">General Disorders and Administration Site Conditions </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span><br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="442120" conceptname="Injection site extravasation">Infusion site extravasation</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4317968" conceptname="Pain in face">Facial pain</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Hepatobiliary Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic function abnormal</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="8" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vulvovaginal candidiasis</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginal infection</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Oral <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="24" valign="top">
<span class="Bold">Investigations </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Gamma-glutamyltransferase increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood alkaline phosphatase increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Hepatic enzyme increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">Electrocardiogram QT prolonged</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood lactate dehydrogenase increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Platelet count increased</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood amylase increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood glucose increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Lipase increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin decreased</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood creatinine increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Transaminases increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">White blood cell count increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood urea increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function test abnormal</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">Hematocrit decreased</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">Prothrombin time prolonged</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Eosinophil count increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated partial thromboplastin time</span> prolonged <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood bilirubin increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Blood triglycerides increased <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">Blood uric acid increased</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="6" valign="top">
<span class="Bold">Metabolism and Nutrition Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="7" valign="top">
<span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">Musculoskeletal chest pain</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="8" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">Tension headache</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="8" valign="top">
<span class="Bold">Psychiatric Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="3" valign="top">
<span class="Bold">Renal and Urinary Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Renal failure acute</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">Vulvovaginal pruritus</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="4" valign="top">
<span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span><br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="7" valign="top">
<span class="Bold">Skin and Subcutaneous Tissue Disorders </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">Dermatitis allergic</span> <br>
</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span> <br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="3" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> </span><br>
</td>
<td class="Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <br>
</td></tr>
<tr class="Last"><td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> <br>
</td></tr>
</tbody>
</table>
<p><span class="Sup">a </span>MedDRA Version 12.0</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Laboratory Changes</h2>
<p class="First">Changes in laboratory parameters, without regard to drug relationship, which are not listed above and which occurred in â‰¥ 2% of patients and at an incidence greater than in controls included: increases in MCH, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, WBCs, PT ratio, <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>, chloride, albumin, globulin, bilirubin; decreases in hemoglobin, RBCs, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, eosinophils, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, PT ratio, glucose, pO<span class="Sub">2</span>, bilirubin, and amylase.Â  It cannot be determined if any of the above laboratory abnormalities were caused by the drug or the underlying condition being treated.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Postmarketing Experience</h2>
<p class="First">Table 4 lists adverse reactions that have been identified during post-approval use of moxifloxacin.Â  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Â </p>
<br><p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â  <span class="Bold">Table 4: Postmarketing Reports of Adverse Drug Reactions</span>Â </p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">System/Organ Class </span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Adverse Reaction </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Blood and Lymphatic System Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span><br><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular tachyarrhythmias</span> (including in very rare cases <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and usually in patients with concurrent severe underlying proarrhythmic conditions) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Ear and Labyrinth Disorders </span><br>
</td>
<td class="Rrule" valign="top">Hearing impairment, including <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> (reversible in majority of cases) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Vision loss</span> (especially in the course of CNS reactions, transient in majority of cases) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Hepatobiliary Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> (predominantly cholestatic) <br><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> (including fatal cases) <br><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> <br>Acute <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span> <br><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> <br><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>) <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4</a>, <a href="#Section_5.5">5.5)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> <br><span class="Italics"><span class="Italics">[seeÂ <a href="#Section_5.1">Warnings and Precautions (5.1)]</a></span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">Altered coordination <br><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.8)</a>]</span></span><br><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span> (exacerbation of) <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>] </span></span><br><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> <br><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> (that may be irreversible), <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.8">Warnings and Precautions (5.8)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Psychiatric Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reaction</span> (very rarely culminating in self-injurious behavior, such as <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/thoughts or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> <span class="Italics"><span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Renal and Urinary Disorders </span><br>
</td>
<td class="Rrule" valign="top">Renal dysfunction <br>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span><br>
</td>
<td class="Rrule" valign="top">Allergic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span></span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Skin and Subcutaneous Tissue Disorders </span><br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> reaction <br><span class="Italics"><span class="Italics">[seeÂ <a href="#Section_5.12">Warnings and Precautions (5.12)</a>] </span></span><br><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> <br><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span> <br><span class="Italics"><span class="Italics">[see <a href="#Section_5.5">Warnings and Precautions (5.5)</a>] </span></span><br>
</td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Warfarin</h2>
<p class="First">Quinolones, including moxifloxacin, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population.Â  In addition, infectious disease and its accompanying inflammatory process, age, and general status of the patient are risk factors for increased anticoagulant activity.Â  Therefore the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if a quinolone is administered concomitantly with warfarin or its derivatives <span class="Italics">[see</span>Â <span class="Italics"><a href="#Section_6.2">Adverse Reactions (6.2</a></span><span class="Italics">,</span><span class="Italics"><a href="#Section_6.3">6.3)</a></span><span class="Italics">, </span><span class="Italics"><a href="#Section_12.3">Pharmacokinetics (12.3)</a></span><span class="Italics">,Â andÂ </span><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span><span class="Italics">]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Antidiabetic Agents</h2>
<p class="First">Disturbances of blood glucose, including <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent.Â  Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered.Â  If a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs, moxifloxacin should be discontinued and appropriate therapy should be initiated immediately <span class="Italics">[seeÂ <a href="#Section_5.11">Warnings and Precautions (5.11</a>),Â <a href="#Section_6.2">Adverse Reactions (6.2)</a>, andÂ <a href="#Section_17">Patient Counseling Information (17)]</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class="First">Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>, and <a href="#Section_17">Patient Counseling Information (17)</a>]</span>.Â Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs that Prolong QT</h2>
<p class="First">There is limited information available on the potential for a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> in humans between moxifloxacin and other drugs that prolong the QTc interval of the electrocardiogram.Â  Sotalol, a Class III antiarrhythmic, has been shown to further increase the QTc interval when combined with high doses of intravenous (IV) moxifloxacin in dogs.Â  Therefore, moxifloxacin should be avoided with Class IA and Class III antiarrhythmics <span class="Italics">[seeÂ <a href="#Section_5.3">Warnings and Precautions (5.3)</a>, <a href="#Section_13.2">Nonclinical Toxicology (13.2)</a>, andÂ <a href="#Section_17">Patient Counseling Information (17)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span> Because no adequate or well-controlled studies have been conducted in pregnant women, moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Â Â </p>
<p>Moxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day or 0.24 times the maximum recommended human dose based on systemic exposure (AUC), but decreased fetal body weights and slightly delayed fetal skeletal development (indicative of fetotoxicity) were observed.Â  Intravenous administration of 80 mg/kg/day (approximately 2 times the maximum recommended human dose based on body surface area) to pregnant rats resulted in maternal toxicity and a marginal effect on fetal and placental weights and the appearance of the placenta.Â  There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at intravenous doses as high as 80 mg/kg/day.Â  Intravenous administration of 20 mg/kg/day (approximately equal to the maximum recommended human oral dose based upon systemic exposure) to pregnant rabbits during organogenesis resulted in decreased fetal body weights and delayed fetal skeletal ossification.Â  When rib and vertebral malformations were combined, there was an increased fetal and litter incidence of these effects.Â  Signs of maternal toxicity in rabbits at this dose included mortality, abortions, marked reduction of food consumption, decreased water intake, body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>.Â  There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> when pregnant cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (2.5 times the maximum recommended human dose based upon systemic exposure).Â  An increased incidence of smaller fetuses was observed at 100 mg/kg/day.Â  In an oral pre- and postnatal development study conducted in rats, effects observed at 500 mg/kg/day included slight increases in duration of pregnancy and prenatal loss, reduced pup birth weight and decreased neonatal survival.Â  Treatment-related maternal mortality occurred during gestation at 500 mg/kg/day in this study.Â </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Moxifloxacin is excreted in the breast milk of rats.Â  Moxifloxacin may also be excreted in human milk.Â  Because of the potential for serious adverse reactions in infants who are nursing from mothers taking moxifloxacin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients and adolescents less than 18 years of age have not been established.Â  Moxifloxacin causes <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in juvenile animals <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>, <a href="#Section_5.10">Warnings and Precautions (5.10)</a>, Â andÂ <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Geriatric patients are at increased risk for developing severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorders</span> including <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> when being treated with a fluoroquinolone such as moxifloxacin.Â  This risk is further increased in patients receiving concomitant corticosteroid therapy.Â  <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">Tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported.Â  Caution should be used when prescribing moxifloxacin to elderly patients especially those on corticosteroids.Â  Patients should be informed of this potential side effect and advised to discontinue moxifloxacin and contact their healthcare provider if any symptoms of <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> occur <span class="Italics">[seeÂ <a href="#Section_0">Boxed Warning,</a>Â <a href="#Section_5.1">Warnings and Precautions (5.1)</a>, andÂ <a href="#Section_6.4">Adverse Reactions (6.4)</a>]</span>.Â </p>
<p>Moxifloxacin injection contains 1,207 mg (52.5 mEq) of sodium per unit dose. Â The geriatric population may respond with a blunted natriuresis to salt loading. Â This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[seeÂ <a href="#Section_5.9">Warnings and Precautions (5.9)</a>]</span>.Â </p>
<p>In controlled multiple-dose clinical trials, 23% of patients receiving oral moxifloxacin were greater than or equal to 65 years of age and 9% were greater than or equal to 75 years of age.Â  The clinical trial data demonstrate that there is no difference in the safety and efficacy of oral moxifloxacin in patients aged 65 or older compared to younger adults.Â Â </p>
<p>In trials of intravenous use, 42% of moxifloxacin patients were greater than or equal to 65 years of age, and 23% were greater than or equal to 75 years of age.Â  The clinical trial data demonstrate that the safety of intravenous moxifloxacin in patients aged 65 or older was similar to that of comparator-treated patients.Â  In general, elderly patients may be more susceptible to drug-associated effects of the QT interval.Â  Therefore, moxifloxacin should be avoided in patients taking drugs that can result in prolongation of the QT interval (for example, Class IA or Class III antiarrhythmics) or in patients with risk factors for <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> (for example, known QT prolongation, uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>,Â <a href="#Section_7.4">Drug Interactions (7.4)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)]</a></span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The pharmacokinetic parameters of moxifloxacin are not significantly altered in mild, moderate, severe, or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.Â  No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those patients requiring hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD) <span class="Italics">[seeÂ <a href="#Section_2">Dosage and Administration (2)</a>, andÂ <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is recommended for mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child-Pugh Classes A, B, or C).Â  However, due to metabolic disturbances associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, which may lead to QT prolongation, moxifloxacin should be used with caution in these patients <span class="Italics">[see <a href="#Section_5.3">Warnings and Precautions (5.3)</a>, andÂ <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Single oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> up to 2.8 g were not associated with any serious adverse events.Â  In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, the stomach should be emptied and adequate hydration maintained.Â  ECG monitoring is recommended due to the possibility of QT interval prolongation.Â  The patient should be carefully observed and given supportive treatment.Â  The administration of activated charcoal as soon as possible after oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may prevent excessive increase of systemic moxifloxacin exposure.Â  About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively.Â Â </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Moxifloxacin is a synthetic broad spectrum antibacterial agent for intravenous administration. Â Moxifloxacin, a fluoroquinolone, is available as a buffered salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Â It is a slightly yellow to yellow crystalline substance. Â Its chemical structure is as follows:Â <br><br><br><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4e28b09-714b-46e7-b4e6-0163cad78fc5&amp;name=moxi-struc.jpg"><br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </p>
<p>Moxifloxacin injection is sterile solution for infusion in a ready-to-use flexible plastic container.Â <br><br><span class="Bold">Moxifloxacin injection</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="631"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Component</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Function</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dosage Formulation</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Moxifloxacin* <br>
</td>
<td class="Rrule" align="center" valign="top">Active ingredient<br>
</td>
<td class="Rrule" align="center" valign="top">400 mg*<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Sodium acetate (added as a trihydrate)<br>
</td>
<td class="Rrule" align="center" valign="top">Tonicity adjuster<br>
</td>
<td class="Rrule" align="center" valign="top">1,702.5 mg<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Disodium sulfate Â <br>
</td>
<td class="Rrule" align="center" valign="top">Tonicity adjuster<br>
</td>
<td class="Rrule" align="center" valign="top">2,840 mg<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Sulfuric acid **<br>
</td>
<td class="Rrule" align="center" valign="top">pH adjustment<br>
</td>
<td class="Rrule" align="center" valign="top">As needed<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Water for injection<br>
</td>
<td class="Rrule" align="center" valign="top">vehicle<br>
</td>
<td class="Rrule" align="center" valign="top">q.s. 250 mL<br>
</td>
</tr>
</tbody></table>
<p>* 400 mg moxifloxacin equivalent to 437.5 mg of moxifloxacin hydrochloride.</p>
<p>**The pH may have been adjusted with sulfuric acid. Â The pH is 5.0 to 6.0. </p>
<br><p>Each mL contains 1.6 mg of moxifloxacin.Â </p>
<p>The appearance of the intravenous solution is clear. Â The plastic container is fabricated from a specially designed multilayer plastic (freeflex<span class="Sup">Â®</span>). Â Solution is in contact with the polypropylene layer of this container and can leach out certain chemical components of the plastic in very small amounts within the expiration period.Â  The leachable compounds were all within acceptable limits based on animal toxicology studies.Â Â </p>
<p>Moxifloxacin injection contains approximately 52.5 mEq (1,207 mg) of sodium in 250 mL.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents <span class="Italics">[see</span>Â <span class="Italics"><a href="#Section_12.4">Microbiology (12.4)</a></span><span class="Italics">]</span>.Â </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The mean (Â±SD) pharmacokinetic parameters of moxifloxacin following single and multiple dose of 400 mg moxifloxacin given by 1 hour intravenous infusion are summarized in Table 5. Â The mean (Â± SD) elimination half-life from plasma is 12 Â± 1.3 hours; steady-state is achieved after at least three days with a 400 mg once daily regimen. Â The absolute bioavailability of moxifloxacin is approximately 90 percent. Â When switching from intravenous to oral formulation, no dosage adjustment is necessary <span class="Italics">[see</span>Â <span class="Italics"><a href="#Section_2.1">Dosage and Administration (2.1)</a>].</span></p>
<br><p><span class="Bold">Table 5: Mean (Â± SD) C</span><span class="Bold"><span class="Sub">max</span></span><span class="Bold">Â </span><span class="Bold">and AUC Values Following Single and Multiple </span></p>
<p><span class="Bold">Doses of 400 mg Moxifloxacin Given by 1 Hour Intravenous Infusion</span><span class="Bold"></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">C</span><span class="Bold"><span class="Sub">max</span></span><span class="Bold"></span><br><span class="Bold">(mg/L)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">AUC</span><br><span class="Bold">(mgâ€¢h/L)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Half-life</span><br><span class="Bold">(hr)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Single Dose IV <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Healthy young male/female (n = 56) <br>
</td>
<td class="Rrule" align="center" valign="top">3.9 Â± 0.9<br>
</td>
<td class="Rrule" align="center" valign="top">39.3 Â± 8.6<br>
</td>
<td class="Rrule" align="center" valign="top">8.2 to 15.4<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Patients (n = 118) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Â Â Â  Male (n = 64) <br>Â Â Â Â  Female (n = 54) <br>Â Â Â Â  &lt; 65 years (n = 58) <br>Â Â Â Â  â‰¥ 65 years (n = 60) <br>
</td>
<td class="Rrule" align="center" valign="top">4.4 Â± 3.7<br>4.5 Â± 2<br>4.6 Â± 4.2<br>4.3 Â± 1.3<br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Multiple Dose IV <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Healthy young male (n = 8) <br>Â  Healthy elderly (n =12; 8 male, 4 female) <br>
</td>
<td class="Rrule" align="center" valign="top">4.2 Â± 0.8<br>6.1 Â± 1.3<br>
</td>
<td class="Rrule" align="center" valign="top">38 Â± 4.7<br>48.2 Â± 0.9<br>
</td>
<td class="Rrule" align="center" valign="top">14.8 Â± 2.2<br>10.1 Â± 1.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Patients<span class="Sup">b</span> (n = 107) <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Â Â Â  Male (n = 58) <br>Â Â Â Â  Female (n = 49) <br>Â Â Â Â  &lt; 65 years (n = 52) <br>Â Â Â Â  â‰¥ 65 years (n = 55) <br>
</td>
<td class="Rrule" align="center" valign="top">4.2 Â± 2.6<br>4.6 Â± 1.5<br>4.1 Â± 1.4<br>4.7 Â± 2.7<br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>Â <br>Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>Â <br>Â <br>Â <br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a</span> Range of means from different studies </p>
<p><span class="Sup">b</span> Expected C<span class="Sub">max</span> (concentration obtained around the time of the end of the infusion) </p>
<br><p><span class="Italics">Distribution </span></p>
<p>Moxifloxacin is approximately 30 to 50% bound to serum proteins, independent of drug concentration. Â The volume of distribution of moxifloxacin ranges from 1.7 to 2.7 L/kg. Â Moxifloxacin is widely distributed throughout the body, with tissue concentrations often exceeding plasma concentrations. Â Moxifloxacin has been detected in the saliva, nasal and bronchial secretions, mucosa of the sinuses, skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid, subcutaneous tissue, skeletal muscle, and abdominal tissues and fluids following oral or intravenous administration of 400 mg. Â Moxifloxacin concentrations measured post-dose in various tissues and fluids following a 400 mg oral or intravenous dose are summarized in Table 6. Â The rates of elimination of moxifloxacin from tissues generally parallel the elimination from plasma.</p>
<br><p><span class="Bold">Table 6: Moxifloxacin Concentrations (mean Â± SD) in Tissues and the Corresponding Plasma <br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Concentrations After a Single 400 mg Oral or Intravenous Dose</span><span class="Bold"><span class="Sup">a</span></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="661"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Tissue or Fluid</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">N</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Plasma Concentration (mcg/mL)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Tissue or Fluid Concentration (mcg/mL or mcg/g)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Tissue Plasma Ratio</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Respiratory</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Alveolar Macrophages Â <br>Â  Bronchial Mucosa <br>Â  Epithelial Lining Fluid <br>
</td>
<td class="Rrule" align="center" valign="top">5<br>8<br>5<br>
</td>
<td class="Rrule" align="center" valign="top">3.3 Â± 0.7<br>3.3 Â± 0.7<br>3.3 Â± 0.7<br>
</td>
<td class="Rrule" align="center" valign="top">61.8 Â± 27.3<br>5.5 Â± 1.3<br>24.4 Â± 14.7<br>
</td>
<td class="Rrule" align="center" valign="top">21.2 Â± 10<br>1.7 Â± 0.3<br>8.7 Â± 6.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Sinus</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Maxillary Sinus Mucosa <br>Â  Anterior Ethmoid Mucosa <br>Â  <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">Nasal Polyps</span> <br>
</td>
<td class="Rrule" align="center" valign="top">4<br>3<br>4<br>
</td>
<td class="Rrule" align="center" valign="top">3.7 Â± 1.1<span class="Sup">b</span><br>3.7 Â± 1.1<span class="Sup">b</span><br>3.7 Â± 1.1<span class="Sup">b</span><br>
</td>
<td class="Rrule" align="center" valign="top">7.6 Â± 1.7<br>8.8 Â± 4.3<br>9.8 Â± 4.5<br>
</td>
<td class="Rrule" align="center" valign="top">2 Â± 0.3<br>2.2 Â± 0.6<br>2.6 Â± 0.6<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Skin, Musculoskeletal</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Fluid <br>Â  Subcutaneous Tissue <br>Â  Skeletal Muscle <br>
</td>
<td class="Rrule" align="center" valign="top">5<br>6<br>6<br>
</td>
<td class="Rrule" align="center" valign="top">3 Â± 0.5<span class="Sup">c</span><br>2.3 Â± 0.4<span class="Sup">d</span><br>2.3 Â± 0.4<span class="Sup">d</span><br>
</td>
<td class="Rrule" align="center" valign="top">2.6 Â± 0.9<br>0.9 Â± 0.3<span class="Sup">e</span><br>0.9 Â± 0.2<span class="Sup">e</span><br>
</td>
<td class="Rrule" align="center" valign="top">0.9 Â± 0.2<br>0.4 Â± 0.6<br>0.4 Â± 0.1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Intra-Abdominal</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â  Abdominal tissue <br>Â  Abdominal exudate <br>Â  <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span> fluid <br>
</td>
<td class="Rrule" align="center" valign="top">8<br>10<br>6<br>
</td>
<td class="Rrule" align="center" valign="top">2.9 Â± 0.5<br>2.3 Â± 0.5<br>2.7 Â± 0.7<br>
</td>
<td class="Rrule" align="center" valign="top">7.6 Â± 2<br>3.5 Â±1.2<br>2.3 Â±1.5<br>
</td>
<td class="Rrule" align="center" valign="top">2.7 Â± 0.8<br>1.6 Â± 0.7<br>0.8 Â± 0.4<br>
</td>
</tr>
</tbody></table>
<p>Â <span class="Sup">a</span> All moxifloxacin concentrations were measured 3 hours after a single 400 mg dose, except the abdominal tissue and exudate concentrations which were measured at 2 hours post-dose and the sinus concentrations which were measured 3 hours post-dose after 5 days of dosing. </p>
<p><span class="Sup">b</span> N = 5 </p>
<p><span class="Sup">c</span> N = 7 </p>
<p><span class="Sup">d</span> N = 12 </p>
<p><span class="Sup">e</span> Reflects only non-protein bound concentrations of drug.</p>
<br><p><span class="Italics">Metabolism </span></p>
<p>Approximately 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation. Â The cytochrome P450 system is not involved in moxifloxacin metabolism, and is not affected by moxifloxacin. Â The sulfate conjugate (M1) accounts for approximately 38% of the dose, and is eliminated primarily in the feces. Â Approximately 14% of an oral or intravenous dose is converted to a glucuronide conjugate (M2), which is excreted exclusively in the urine. Â Peak plasma concentrations of M2 are approximately 40% those of the parent drug, while plasma concentrations of M1 are generally less than 10% those of moxifloxacin.Â Â </p>
<p><span class="Italics">In vitro </span>studies with cytochrome (CYP) P450 enzymes indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, suggesting that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes. <br><br><span class="Italics">Excretion </span></p>
<p>Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces). Â A total of 96% Â± 4% of an oral dose is excreted as either unchanged drug or known metabolites. Â The mean (Â± SD) apparent total body clearance and renal clearance are 12 Â± 2 L/hr and 2.6 Â± 0.5 L/hr, respectively. <br><span class="Italics"><br>Pharmacokinetics in Specific Populations </span></p>
<p><span class="Underline">Geriatric </span></p>
<p>Following oral administration of 400 mg moxifloxacin for 10 days in 16 elderly (8 male; 8 female) and 17 young (8 male; 9 female) healthy volunteers, there were no age-related changes in moxifloxacin pharmacokinetics. Â In 16 healthy male volunteers (8 young; 8 elderly) given a single 200 mg dose of oral moxifloxacin, the extent of systemic exposure (AUC and C<span class="Sub">max</span>) was not statistically different between young and elderly males and elimination half-life was unchanged. Â No dosage adjustment is necessary based on age. Â In large phase III studies, the concentrations around the time of the end of the infusion in elderly patients following intravenous infusion of 400 mg were similar to those observed in young patients <span class="Italics">[seeÂ <a href="#Section_8.5">Use in Specific Populations (8.5)</a>].</span><span class="Italics">Â </span></p>
<p><span class="Underline">Pediatric </span></p>
<p>The pharmacokinetics of moxifloxacin in pediatric subjects has not been studied <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a>].Â </span>Â </p>
<p><span class="Underline">Gender </span></p>
<p>Following oral administration of 400 mg moxifloxacin daily for 10 days to 23 healthy males (19 to 75 years) and 24 healthy females (19 to 70 years), the mean AUC and C<span class="Sub">max</span> were 8% and 16% higher, respectively, in females compared to males. Â There are no significant differences in moxifloxacin pharmacokinetics between male and female subjects when differences in body weight are taken into consideration.Â Â </p>
<p>A 400 mg single dose study was conducted in 18 young males and females. Â The comparison of moxifloxacin pharmacokinetics in this study (9 young females and 9 young males) showed no differences in AUC or C<span class="Sub">max</span> due to gender. Â Dosage adjustments based on genderÂ are not necessary.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </p>
<p><span class="Underline">Race </span></p>
<p>Steady-state moxifloxacin pharmacokinetics in male Japanese subjects were similar to those determined in Caucasians, with a mean C<span class="Sub">max</span> of 4.1 mcg/mL, an AUC<span class="Sub">24</span> of 47 mcgâ€¢h/mL, and an elimination half-life of 14 hours, following 400 mg p.o. daily.Â Â </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> </span></p>
<p>The pharmacokinetic parameters of moxifloxacin are not significantly altered in mild, moderate, severe, or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Â No dosage adjustment is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those patients requiring hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD).Â Â </p>
<p>In a single oral dose study of 24 patients with varying degrees of renal function from normal to severely impaired, the mean peak concentrations (C<span class="Sub">max</span>) of moxifloxacin were reduced by 21% and 28% in the patients with moderate (CL<span class="Sub">CR</span> â‰¥ 30 and â‰¤ 60 mL/min) and severe (CL<span class="Sub">CR</span> &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively. Â The mean systemic exposure (AUC) in these patients was increased by 13%. Â In the moderate and severe renally impaired patients, the mean AUC for the sulfate conjugate (M1) increased by 1.7-fold (ranging up to 2.8-fold) and mean AUC and C<span class="Sub">max</span> for the glucuronide conjugate (M2) increased by 2.8-fold (ranging up to 4.8-fold) and 1.4-fold (ranging up to 2.5-fold), respectively <span class="Italics">[seeÂ Use in Specific Populations (8.6)].Â </span>Â </p>
<p>The pharmacokinetics of single dose and multiple dose moxifloxacin were studied in patients with CL<span class="Sub">CR</span> &lt; 20 mL/min on either hemodialysis or continuous ambulatory peritoneal dialysis (8 HD, 8 CAPD). Â Following a single 400 mg oral dose, the AUC of moxifloxacin in these HD and CAPD patients did not vary significantly from the AUC generally found in healthy volunteers. Â C<span class="Sub">max</span> values of moxifloxacin were reduced by about 45% and 33% in HD and CAPD patients, respectively, compared to healthy, historical controls. Â The exposure (AUC) to the sulfate conjugate (M1) increased by 1.4- to 1.5-fold in these patients. Â The mean AUC of the glucuronide conjugate (M2) increased by a factor of 7.5, whereas the mean C<span class="Sub">max</span> values of the glucuronide conjugate (M2) increased by a factor of 2.5 to 3, compared to healthy subjects. Â The sulfate and the glucuronide conjugates of moxifloxacin are not microbiologically active, and the clinical implication of increased exposure to these metabolites in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> including those undergoing HD and CAPD has not been studied.Â Â </p>
<p>Oral administration of 400 mg QD moxifloxacin for 7 days to patients on HD or CAPD produced mean systemic exposure (AUC<span class="Sub">ss</span>) to moxifloxacin similar to that generally seen in healthy volunteers. Â Steady-state C<span class="Sub">max</span> values were about 22% lower in HD patients but were comparable between CAPD patients and healthy volunteers. Â Both HD and CAPD removed only small amounts of moxifloxacin from the body (approximately 9% by HD, and 3% by CAPD). Â HD and CAPD also removed about 4% and 2% of the glucuronide metabolite (M2), respectively. </p>
<p>Â <span class="Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> </span></p>
<p>No dosage adjustment is recommended for mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child-Pugh Classes A, B, or C). Â However, due to metabolic disturbances associated with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, which may lead to QT prolongation, moxifloxacin should be used with caution in these patients <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_5.3">Warnings and Precautions (5.3)</a> andÂ <a href="#Section_8.7">Use in Specific Populations (8.7)</a>].</span></p>
<p>In 400 mg single oral dose studies in 6 patients with mild (Child-Pugh Class A) and 10 patients with moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, moxifloxacin mean systemic exposure (AUC) was 78% and 102%, respectively, of 18 healthy controls and mean peak concentration (C<span class="Sub">max</span>) was 79% and 84% of controls.Â Â </p>
<p>The mean AUC of the sulfate conjugate of moxifloxacin (M1) increased by 3.9-fold (ranging up to 5.9-fold) and 5.7-fold (ranging up to 8-fold) in the mild and moderate groups, respectively. Â The mean C<span class="Sub">max</span> of M1 increased by approximately 3-fold in both groups (ranging up to 4.7- and 3.9-fold). Â The mean AUC of the glucuronide conjugate of moxifloxacin (M2) increased by 1.5-fold (ranging up to 2.5-fold) in both groups. Â The mean C<span class="Sub">max</span> of M2 increased by 1.6- and 1.3-fold (ranging up to 2.7- and 2.1-fold), respectively. Â The clinical significance of increased exposure to the sulfate and glucuronide conjugates has not been studied. Â In a subset of patients participating in a clinical trial, the plasma concentrations of moxifloxacin and metabolites determined approximately at the moxifloxacin T<span class="Sub">max</span> following the first intravenous or oral moxifloxacin dose in the Child-Pugh Class C patients (n = 10) were similar to those in the Child-Pugh Class A/B patients (n = 5), and also similar to those observed in healthy volunteer studies.Â Â </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> Potential </span></p>
<p>A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per group) demonstrated that moxifloxacin does not show <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> in comparison to placebo. Â The minimum erythematous dose (MED) was measured before and after treatment with moxifloxacin (200 mg or 400 mg once daily), lomefloxacin (400 mg once daily), or placebo. Â In this study, the MED measured for both doses of moxifloxacin were not significantly different from placebo, while lomefloxacin significantly lowered the MED.Â Â </p>
<p>It is difficult to ascribe relative <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> among various fluoroquinolones during actual patient use because other factors play a role in determining a subjectâ€™s susceptibility to this adverse event such as: a patientâ€™s <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span>, frequency and duration of sun and artificial ultraviolet light (UV) exposure, wearing of sunscreen and protective clothing, the use of other concomitant drugs and the dosage and duration of fluoroquinolone therapy <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_5.12">Warnings and Precautions (5.12)</a></span><span class="Italics">,Â </span><span class="Italics"><a href="#Section_6.3">Adverse ReactionsÂ (6.3)</a></span><span class="Italics">, and</span>Â <span class="Italics"><span class="Italics"><a href="#Section_17">Patient Counseling Information (17)</a></span>].</span>Â Â </p>
<br><p><span class="Italics">Drug-Drug Interactions </span></p>
<p>The following drug interactions were studied in healthy volunteers or patients.Â Â Â </p>
<p>Digoxin, itraconazole, morphine, probenecid, ranitidine, theophylline and warfarin did not significantly affect the pharmacokinetics of moxifloxacin. Â These results and the data from <span class="Italics">in vitro </span>studies suggest that moxifloxacin is unlikely to significantly alter the metabolic clearance of drugs metabolized by CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 enzymes.Â Â </p>
<p>Moxifloxacin had no clinically significant effect on the pharmacokinetics of atenolol, digoxin, glyburide, itraconazole, oral contraceptives, theophylline, cyclosporine and warfarin <span class="Italics">[seeÂ <span class="Italics"><a href="#Section_7.1">Drug Interactions (7.1)</a></span>].Â </span>Â </p>
<p><span class="Underline">Atenolol </span></p>
<p>In a crossover study involving 24 healthy volunteers (12 male; 12 female), the mean atenolol AUC following a single oral dose of 50 mg atenolol with placebo was similar to that observed when atenolol was given concomitantly with a single 400 mg oral dose of moxifloxacin. Â The mean C<span class="Sub">max</span> of single dose atenolol decreased by about 10% following co-administration with a single dose of moxifloxacin.Â Â </p>
<p><span class="Underline">Digoxin </span></p>
<p>No significant effect of moxifloxacin (400 mg once daily for two days) on digoxin (0.6 mg as a single dose) AUC was detected in a study involving 12 healthy volunteers. Â The mean digoxin C<span class="Sub">max</span> increased by about 50% during the distribution phase of digoxin. Â This transient increase in digoxin C<span class="Sub">max</span> is not viewed to be clinically significant. Â Moxifloxacin pharmacokinetics were similar in the presence or absence of digoxin. Â No dosage adjustment for moxifloxacin or digoxin is required when these drugs are administered concomitantly.Â Â </p>
<p><span class="Underline">Glyburide </span></p>
<p>In diabetics, glyburide (2.5 mg once daily for two weeks pretreatment and for five days concurrently) mean AUC and C<span class="Sub">max</span> were 12% and 21% lower, respectively, when taken with moxifloxacin (400 mg once daily for five days) in comparison to placebo. Â Nonetheless, blood glucose levels were decreased slightly in patients taking glyburide and moxifloxacin in comparison to those taking glyburide alone, suggesting no interference by moxifloxacin on the activity of glyburide. Â These interaction results are not viewed as clinically significant.Â Â </p>
<p><span class="Underline">Itraconazole </span></p>
<p>In a study involving 11 healthy volunteers, there was no significant effect of itraconazole (200 mg once daily for 9 days), a potent inhibitor of cytochrome P4503A4, on the pharmacokinetics of moxifloxacin (a single 400 mg dose given on the 7th<span class="Sup">Â </span>day of itraconazole dosing). Â In addition, moxifloxacin was shown not to affect the pharmacokinetics of itraconazole.Â Â </p>
<p><span class="Underline">Morphine </span></p>
<p>No significant effect of morphine sulfate (a single 10 mg intramuscular dose) on the mean AUC and C<span class="Sub">max</span> of moxifloxacin (400 mg single dose) was observed in a study of 20 healthy male and female volunteers.Â Â </p>
<p><span class="Underline">Oral Contraceptives </span></p>
<p>A placebo-controlled study in 29 healthy female subjects showed that moxifloxacin 400 mg daily for 7 days did not interfere with the hormonal suppression of oral contraception with 0.15 mg levonorgestrel/0.03 mg ethinylestradiol (as measured by serum progesterone, FSH, estradiol, and LH), or with the pharmacokinetics of the administered contraceptive agents. </p>
<p>Â <span class="Underline">Probenecid </span></p>
<p>Probenecid (500 mg twice daily for two days) did not alter the renal clearance and total amount of moxifloxacin (400 mg single dose) excreted renally in a study of 12 healthy volunteers.Â Â </p>
<p><span class="Underline">Ranitidine </span></p>
<p>No significant effect of ranitidine (150 mg twice daily for three days as pretreatment) on the pharmacokinetics of moxifloxacin (400 mg single dose) was detected in a study involving 10 healthy volunteers.Â Â </p>
<p><span class="Underline">Theophylline </span></p>
<p>No significant effect of moxifloxacin (200 mg every twelve hours for 3 days) on the pharmacokinetics of theophylline (400 mg every twelve hours for 3 days) was detected in a study involving 12 healthy volunteers. Â In addition, theophylline was not shown to affect the pharmacokinetics of moxifloxacin. Â The effect of co-administration of a 400 mg dose of moxifloxacin with theophylline has not been studied, but it is not expected to be clinically significant based on <span class="Italics">in vitro </span>metabolic data showing that moxifloxacin does not inhibit the CYP1A2 isoenzyme.Â </p>
<p><span class="Underline">Warfarin </span></p>
<p>No significant effect of moxifloxacin (400 mg once daily for eight days) on the pharmacokinetics of R- and S-warfarin (25 mg single dose of warfarin sodium on the fifth day) was detected in a study involving 24 healthy volunteers. Â No significant change in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time was observed <span class="Italics">[seeÂ </span><span class="Italics"><a href="#Section_6.2">Adverse Reactions (6.2)</a></span>Â <span class="Italics">and</span>Â <span class="Italics"><a href="#Section_7.1">Drug Interactions (7.1)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Italics">Mechanism of Action </span></p>
<p>The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination.Â  It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety.Â  The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <span class="Italics">NorA</span> or <span class="Italics">pmrA</span> genes seen in certain Gram-positive bacteria. </p>
<br><p><span class="Italics">Mechanism of Resistance </span></p>
<p>The mechanism of action for fluoroquinolones, including moxifloxacin, is different from that of macrolides, beta-lactams, aminoglycosides, or tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to moxifloxacin.Â  Resistance to fluoroquinolones occurs primarily by a mutation in topoisomerase II (DNA gyrase) or topoisomerase IV genes, decreased outer membrane permeability or drug efflux.Â  <span class="Italics">In vitro</span> resistance to moxifloxacin develops slowly via multiple-step mutations.Â  Resistance to moxifloxacin occurs <span class="Italics">in vitro</span> at a general frequency of between 1.8 x 10<span class="Sup">-9</span> to &lt; 1 x 10<span class="Sup">-11</span> for Gram-positive bacteria. </p>
<br><p><span class="Italics">Cross-Resistance </span></p>
<p>Cross-resistance has been observed between moxifloxacin and other fluoroquinolones against Gram-negative bacteria.Â  Gram-positive bacteria resistant to other fluoroquinolones may, however, still be susceptible to moxifloxacin.Â  There is no known cross-resistance between moxifloxacin and other classes of antimicrobials.Â </p>
<p>Moxifloxacin has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[seeÂ <a href="#Section_1">Indications and Usage (1)]</a></span>. </p>
<br><p><span class="Bold">Gram-positive bacteria </span></p>
<p>â€¢ <span class="Italics">Enterococcus faecalis</span></p>
<p>â€¢ <span class="Italics">Staphylococcus aureus</span></p>
<p>â€¢ <span class="Italics">Streptococcus anginosus</span></p>
<p>â€¢ <span class="Italics">Streptococcus constellatus</span></p>
<p>â€¢ <span class="Italics">Streptococcus pneumoniae</span> (including multi-drug resistant isolates [MDRSP]**)</p>
<p>â€¢ <span class="Italics">Streptococcus pyogenes</span></p>
<br><p>**MDRSP, Multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. pneumoniae</span>), and are isolates resistant to two or more of the following antibacterial drugs: penicillin (MIC) â‰¥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. </p>
<br><p><span class="Bold">Gram-negative bacteria </span></p>
<p>â€¢ <span class="Italics">Enterobacter cloacae</span></p>
<p>â€¢ <span class="Italics">Escherichia coli</span></p>
<p>â€¢ <span class="Italics">Haemophilus influenzae</span></p>
<p>â€¢ <span class="Italics">Haemophilus parainfluenzae</span></p>
<p>â€¢ <span class="Italics">Klebsiella pneumoniae</span></p>
<p>â€¢ <span class="Italics">Moraxella catarrhalis</span></p>
<p>â€¢ <span class="Italics">Proteus mirabilis</span></p>
<br><p><span class="Bold">Anaerobic bacteria </span></p>
<p>â€¢ <span class="Italics">Bacteroides fragilis</span></p>
<p>â€¢ <span class="Italics">Bacteroides thetaiotaomicron</span></p>
<p>â€¢ <span class="Italics">Clostridium perfringens</span></p>
<p>â€¢ <span class="Italics">Peptostreptococcus</span> species </p>
<br><p><span class="Bold">Other microorganisms </span></p>
<p>â€¢ <span class="Italics">Chlamydophila pneumoniae</span></p>
<p>â€¢ <span class="Italics">Mycoplasma pneumoniae</span></p>
<br><p>The following <span class="Italics">in vitro</span> data are available, <span class="Underline">but their clinical significance is unknown</span>.Â  At least 90 percent of the following bacteria exhibit an <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to 1 mcg/mL for moxifloxacin.Â  However, the efficacy of moxifloxacin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria has not been established in adequate and well controlled clinical trials. </p>
<br><p><span class="Bold">Gram-positive bacteria </span></p>
<p>â€¢ <span class="Italics">Staphylococcus epidermidis</span></p>
<p>â€¢ <span class="Italics">Streptococcus agalactiae</span></p>
<p>â€¢ <span class="Italics">Streptococcus</span> viridans group </p>
<br><p><span class="Bold">Gram-negative bacteria </span></p>
<p>â€¢ <span class="Italics">Citrobacter freundii</span></p>
<p>â€¢ <span class="Italics">Klebsiella oxytoca</span></p>
<p>â€¢ <span class="Italics">Legionella pneumophila</span></p>
<br><p><span class="Bold">Anaerobic bacteria </span></p>
<p>â€¢ <span class="Italics">Fusobacterium</span> species </p>
<p>â€¢ <span class="Italics">Prevotella</span> species </p>
<br><p><span class="Italics">Susceptibility Tests Methods </span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community acquired pathogens.Â  These reports should aid the physician in selecting an antibacterial drug product for treatment. </p>
<br><p>â€¢ <span class="Bold">Dilution Techniques:</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).Â  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.Â  The MICs should be determined using a standardized procedure.Â  Standardized procedures are based on a dilution method (broth and/or agar).<span class="Sup">1</span>Â  The MIC values should be interpreted according to the criteria in Table 7. </p>
<br><p>â€¢ <span class="Bold">Diffusion Techniques:</span></p>
<p>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.Â  The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds.Â  The zone size prove should be determined using a standardized test method.<span class="Sup">2,3</span>Â  This procedure uses paper disks impregnated with 5 mcg moxifloxacin to test the susceptibility of bacteria to moxifloxacin.Â  The disc diffusion interpretive criteria are provided in Table 7.</p>
<br><p>â€¢ <span class="Bold">Anaerobic Techniques:</span></p>
<p>For anaerobic bacteria, the susceptibility to moxifloxacin can be determined by a standardized test method.<span class="Sup">4</span>Â  The MIC values obtained should be interpreted according to the criteria provided in Table 7.</p>
<br><p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Table 7: Susceptibility Test Interpretive Criteria for Moxifloxacin</span>Â </p>
<table border="0" cellpadding="0" cellspacing="0" width="606"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold">MIC (mcg/mL)</span><br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Zone Diameter (mm)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Species </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">S</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">I</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">R</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">S</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">I</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">R</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterobacteriacae </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 8<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 19<br>
</td>
<td class="Rrule" align="center" valign="top">16 to 18<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 15<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterococcus faecalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 18<br>
</td>
<td class="Rrule" align="center" valign="top">15 to 17<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 8<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 19<br>
</td>
<td class="Rrule" align="center" valign="top">16 to 18<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 15<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 18<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus parainfluenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 18<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 18<br>
</td>
<td class="Rrule" align="center" valign="top">15 to 17<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus </span>species<span class="Italics"></span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 18<br>
</td>
<td class="Rrule" align="center" valign="top">15 to 17<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 14<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Anaerobic bacteria <br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 8<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
</tbody></table>
<p>S=susceptible, I=Intermediate, and R=resistant.</p>
<p><span class="Sup">a</span>Â The current absence of data on moxifloxacin-resistant isolates precludes defining any Â </p>
<p>Â Â  results other than â€œSusceptibleâ€?. Â Isolates yielding test results (MIC or zone diameter) other </p>
<p>Â Â  than susceptible, should be submitted to a reference laboratory for additional testing.</p>
<br><p>A report of â€œSusceptibleâ€? indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen.Â  A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.Â  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of the drug product can be used.Â  This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation.Â  A report of â€œResistantâ€? indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected. </p>
<p>â€¢ <span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay and the techniques of the individuals performing the test.<span class="Sup">1,2,3,4</span>Â  Standard moxifloxacin powder should provide the following range of MIC values noted in Table 8.Â  For the diffusion technique using the 5 mcg moxifloxacin disk, the criteria in Table 8 should be achieved.<br>Â Â Â Â Â Â Â Â Â Â Â  </p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â  Â Â  </span><span class="Bold">Table 8: Acceptable Quality Control Ranges for Moxifloxacin</span>Â </p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto 6.75pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">MIC range (mcg/mL)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Zone Diameter (mm)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterococcus faecalis </span>ATCC 29212 <br>
</td>
<td class="Rrule" align="center" valign="top">0.06 to 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Escherichia coli </span><br>ATCC 25922 <br>
</td>
<td class="Rrule" align="center" valign="top">0.008 to 0.06<br>
</td>
<td class="Rrule" align="center" valign="top">28 to 35<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49247 <br>
</td>
<td class="Rrule" align="center" valign="top">0.008 to 0.03<br>
</td>
<td class="Rrule" align="center" valign="top">31 to 39<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span>ATCC 29213 <br>
</td>
<td class="Rrule" align="center" valign="top">0.015 to 0.06<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span>ATCC 25923 <br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">28 to 35<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae </span>ATCC 49619 <br>
</td>
<td class="Rrule" align="center" valign="top">0.06 to 0.25<br>
</td>
<td class="Rrule" align="center" valign="top">25 to 31<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Bacteroides fragilis </span><br>ATCC 25285 <br>
</td>
<td class="Rrule" align="center" valign="top">0.125 to 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Bacteroides thetaiotaomicron </span><br>ATCC 29741 <br>
</td>
<td class="Rrule" align="center" valign="top">1 to 4<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Eubacterium lentum </span><br>ATCC 43055 <br>
</td>
<td class="Rrule" align="center" valign="top">0.125 to 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
</tbody></table>
<br>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. </p>
<br><p>Moxifloxacin was not mutagenic in 4 bacterial <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (TA 98, TA 100, TA 1535, TA 1537) used in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> reversion assay.Â  As with other quinolones, the positive response observed with moxifloxacin in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA 102 using the same assay may be due to the inhibition of DNA gyrase.Â  Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay.Â  An equivocal result was obtained in the same assay when v79 cells were used.Â  Moxifloxacin was clastogenic in the v79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes.Â  There was no evidence of genotoxicity <span class="Italics">in vivo</span> in a micronucleus test or a dominant lethal test in mice. </p>
<br><p>Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, (approximately 12 times the maximum recommended human dose based on body surface area), or at intravenous doses as high as 45 mg/kg/day, (approximately equal to the maximum recommended human dose based on body surface area).Â  At 500 mg/kg orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.Â </p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Quinolones have been shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals.Â  In studies in juvenile dogs oral doses of moxifloxacin â‰¥ 30 mg/kg/day (approximately 1.5 times the maximum recommended human dose based upon systemic exposure) for 28 days resulted in <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>.Â  There was no evidence of <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in mature monkeys and rats at oral doses up to 135 and 500 mg/kg/day, respectively. </p>
<br><p>Moxifloxacin at an oral dose of 300 mg/kg did not show an increase in acute toxicity or potential for CNS toxicity (for example, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) in mice when used in combination with NSAIDs such as diclofenac, ibuprofen, or fenbufen.Â  Some quinolones have been reported to have proconvulsant activity that is exacerbated with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs). </p>
<br><p>A QT-prolonging effect of moxifloxacin was found in dog studies, at plasma concentrations about five times the human therapeutic level.Â  The combined infusion of sotalol, a Class III antiarrhythmic agent, with moxifloxacin induced a higher degree of QTc prolongation in dogs than that induced by the same dose (30 mg/kg) of moxifloxacin alone.Â  Electrophysiological <span class="Italics">in vitro</span> studies suggested an inhibition of the rapid activating component of the delayed rectifier potassium current (I<span class="Sub">Kr</span>) as an underlying mechanism. </p>
<br><p>No signs of local intolerability were observed in dogs when moxifloxacin was administered intravenously.Â  After intra-arterial injection, inflammatory changes involving the peri-arterial soft tissue were observed suggesting that intra-arterial administration of moxifloxacin should be avoided.Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute Bacterial Exacerbation of Chronic Bronchitis</span></h2>
<p class="First">Moxifloxacin tablets (400 mg once daily for five days) were evaluated for the treatment of <span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">acute bacterial exacerbation of chronic bronchitis</span> in a randomized, double-blind, controlled clinical trial conducted in the US.Â  This study compared moxifloxacin with clarithromycin (500 mg twice daily for 10 days) and enrolled 629 patients.Â  Clinical success was assessed at 7 to 17 days post-therapy.Â  The clinical success for moxifloxacin was 89% (222/250) compared to 89% (224/251) for clarithromycin.Â </p>
<br><p><span class="Bold">Table 9: Clinical Success Rates at Follow-Up Visit for <br>Clinically Evaluable Patients </span><span class="Bold">by Pathogen (Acute Bacterial <br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Exacerbation of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span>)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 0.9in"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Pathogen</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Moxifloxacin</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Clarithromycin</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">16/16 (100%)<br>
</td>
<td class="Rrule" align="center" valign="top">20/23 (87%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">33/37 (89%)<br>
</td>
<td class="Rrule" align="center" valign="top">36/41 (88%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus parainfluenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">16/16 (100%)<br>
</td>
<td class="Rrule" align="center" valign="top">14/14 (100%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Moraxella catarrhalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">29/34 (85%)<br>
</td>
<td class="Rrule" align="center" valign="top">24/24 (100%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span><br>
</td>
<td class="Rrule" align="center" valign="top">15/16 (94%)<br>
</td>
<td class="Rrule" align="center" valign="top">6/8 (75%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Klebsiella pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">18/20 (90%)<br>
</td>
<td class="Rrule" align="center" valign="top">10/11 (91%)<br>
</td>
</tr>
</tbody></table>
<br><p>The microbiological eradication rates (eradication plus presumed eradication) in moxifloxacin-treated patients were <span class="Italics">Streptococcus pneumoniae</span> 100%, <span class="Italics">Haemophilus influenzae</span> 89%, <span class="Italics">Haemophilus parainfluenzae</span> 100%, <span class="Italics">Moraxella catarrhalis</span> 85%, <span class="Italics">Staphylococcus aureus</span> 94%, and <span class="Italics">Klebsiella pneumoniae</span> 85%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span></h2>
<p class="First">A randomized, double-blind, controlled clinical trial was conducted in the US to compare the efficacy of moxifloxacin tablets (400 mg once daily) to that of high-dose clarithromycin (500 mg twice daily) in the treatment of patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>.Â  This study enrolled 474 patients (382 of whom were valid for the efficacy analysis conducted at the 14 to 35 day follow-up visit).Â  Clinical success for clinically evaluable patients was 95% (184/194) for moxifloxacin and 95% (178/188) for high dose clarithromycin.Â  </p>
<br><p>A randomized, double-blind, controlled trial was conducted in the US and Canada to compare the efficacy of sequential IV/PO moxifloxacin 400 mg QD for 7 to 14 days to an IV/PO fluoroquinolone control (trovafloxacin or levofloxacin) in the treatment of patients with clinically and radiologically documented <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>.Â  This study enrolled 516 patients, 362 of whom were valid for the efficacy analysis conducted at the 7 to 30 day post-therapy visit.Â  The clinical success rate was 86% (157/182) for moxifloxacin therapy and 89% (161/180) for the fluoroquinolone comparators. </p>
<br><p>An open-label ex-US study that enrolled 628 patients compared moxifloxacin to sequential IV/PO amoxicillin/clavulanate (1.2 g IV q8h/625 mg PO q8h) with or without high-dose IV/PO clarithromycin (500 mg BID).Â  The intravenous formulations of the comparators are not FDA approved.Â  The clinical success rate at Day 5 to 7 for moxifloxacin therapy was 93% (241/258) and demonstrated superiority to amoxicillin/clavulanate Â± clarithromycin (85%, 239/280) [95% C.I. of difference in success rates between moxifloxacin and comparator (2.9%, 13.2%)].Â  The clinical success rate at the 21 to 28 days post-therapy visit for moxifloxacin was 84% (216/258), which also demonstrated superiority to the comparators (74%, 208/280) [95% C.I. of difference in success rates between moxifloxacin and comparator (2.6%, 16.3%)].</p>
<br><p>The clinical success rates by pathogen across four CAP studies are presented in Table 10.Â  </p>
<br><p><span class="Bold">Table 10: Clinical Success Rates byÂ <br>Â Â Â Â Pathogen (Pooled CAP Studies)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 58.8pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Pathogen</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Moxifloxacin</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">80/85<br>
</td>
<td class="Rrule" align="center" valign="top">(94%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span><br>
</td>
<td class="Rrule" align="center" valign="top">17/20<br>
</td>
<td class="Rrule" align="center" valign="top">(85%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Klebsiella pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">11/12<br>
</td>
<td class="Rrule" align="center" valign="top">(92%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae </span><br>
</td>
<td class="Rrule" align="center" valign="top">56/61<br>
</td>
<td class="Rrule" align="center" valign="top">(92%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Chlamydophila pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">119/128<br>
</td>
<td class="Rrule" align="center" valign="top">(93%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Mycoplasma pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">73/76<br>
</td>
<td class="Rrule" align="center" valign="top">(96%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Moraxella catarrhalis </span><br>
</td>
<td class="Rrule" align="center" valign="top">11/12<br>
</td>
<td class="Rrule" align="center" valign="top">(92%)<br>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span> Caused by Multi-Drug Resistant Streptococcus pneumoniae (MDRSP)</h2>
<p class="First">Moxifloxacin was effective in the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span> (CAP) caused by multi-drug resistant MDRSP* isolates.Â  Of 37 microbiologically evaluable patients with MDRSP isolates, 35 patients (95%) achieved clinical and bacteriological success post-therapy.Â  The clinical and bacteriological success rates based on the number of patients treated are shown in Table 11. </p>
<br><p>* MDRSP, Multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span> includes isolates previously known as PRSP (Penicillin-resistant <span class="Italics">S. pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin (MIC â‰¥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.Â  </p>
<br><p><span class="Bold">Â Â Â  Table 11: Clinical and Bacteriological Success Rates for Moxifloxacin-Treated </span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â  Â MDRSP CAP Patients (Population: Valid for Efficacy)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="606"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Screening Susceptibility</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Clinical Success</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Bacteriological Success</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">n/N<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">%<br>
</td>
<td class="Rrule" align="center" valign="top">n/N<span class="Sup">b</span><br>
</td>
<td class="Rrule" align="center" valign="top">%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Penicillin-resistant <br>
</td>
<td class="Rrule" align="center" valign="top">21/21<br>
</td>
<td class="Rrule" align="center" valign="top">100%<span class="Sup">c</span><br>
</td>
<td class="Rrule" align="center" valign="top">21/21<br>
</td>
<td class="Rrule" align="center" valign="top">100%<span class="Sup">c</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">2nd generation cephalosporin-resistant <br>
</td>
<td class="Rrule" align="center" valign="top">25/26<br>
</td>
<td class="Rrule" align="center" valign="top">96%<span class="Sup">c</span><br>
</td>
<td class="Rrule" align="center" valign="top">25/26<br>
</td>
<td class="Rrule" align="center" valign="top">96%<span class="Sup">c</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Macrolide-resistant<span class="Sup">d</span><br>
</td>
<td class="Rrule" align="center" valign="top">22/23<br>
</td>
<td class="Rrule" align="center" valign="top">96%<br>
</td>
<td class="Rrule" align="center" valign="top">22/23<br>
</td>
<td class="Rrule" align="center" valign="top">96%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Trimethoprim/sulfamethoxazole-resistant <br>
</td>
<td class="Rrule" align="center" valign="top">28/30<br>
</td>
<td class="Rrule" align="center" valign="top">93%<br>
</td>
<td class="Rrule" align="center" valign="top">28/30<br>
</td>
<td class="Rrule" align="center" valign="top">93%<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Tetracycline-resistant <br>
</td>
<td class="Rrule" align="center" valign="top">17/18<br>
</td>
<td class="Rrule" align="center" valign="top">94%<br>
</td>
<td class="Rrule" align="center" valign="top">17/18<br>
</td>
<td class="Rrule" align="center" valign="top">94%<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a</span> n = number of patients successfully treated; N = number of patients with MDRSP (from a </p>
<p>Â  total of Â Â 37 patients) </p>
<p><span class="Sup">b</span> n = number of patients successfully treated (presumed eradication or eradication); </p>
<p>Â Â  N = number of patients with MDRSP (from a total of 37 patients)</p>
<p><span class="Sup">c</span> One patient had a respiratory isolate that was resistant to penicillin and cefuroxime but a </p>
<p>Â Â  blood isolate that was intermediate to penicillin and cefuroxime. Â The patient is included in </p>
<p>Â  Â the database based on the respiratory isolate. </p>
<p><span class="Sup">d</span> Azithromycin, clarithromycin, and erythromycin were the macrolide antimicrobials tested. </p>
<br><p>Not all isolates were resistant to all antimicrobial classes tested.Â  Success and eradication rates are summarized in Table 12. </p>
<br><p><span class="Bold">Table 12: Clinical Success Rates and Microbiological Eradication Rates for Resistant </span></p>
<p><span class="Bold"><span class="Italics">Â Â Â Â Â Â Â  Â Â Â  Streptococcus pneumoniae </span></span><span class="Bold">(<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Community Acquired Pneumonia</span>)</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="606"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold"><span class="Italics">S. pneumoniae </span></span><span class="Bold">with MDRSP</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Clinical Success</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Bacteriological Eradication Rate</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Resistant to 2 antimicrobials <br>
</td>
<td class="Rrule" align="center" valign="top">12/13 (92.3%)<br>
</td>
<td class="Rrule" align="center" valign="top">12/13 (92.3%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Resistant to 3 antimicrobials <br>
</td>
<td class="Rrule" align="center" valign="top">10/11 (90.9%)<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">10/11 (90.9%)<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Resistant to 4 antimicrobials <br>
</td>
<td class="Rrule" align="center" valign="top">6/6 (100%)<br>
</td>
<td class="Rrule" align="center" valign="top">6/6 (100%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Resistant to 5 antimicrobials <br>
</td>
<td class="Rrule" align="center" valign="top">7/7 (100%)<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">7/7 (100%)<span class="Sup">a</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span> with MDRSP <br>
</td>
<td class="Rrule" align="center" valign="top">9/9 (100%)<br>
</td>
<td class="Rrule" align="center" valign="top">9/9 (100%)<br>
</td>
</tr>
</tbody></table>
<p>Â <span class="Sup">a</span> One patient had a respiratory isolate resistant to 5 antimicrobials and a blood isolate </p>
<p>Â  resistant to 3 antimicrobials. Â The patient was included in the category resistant to 5 </p>
<p>Â  antimicrobials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></h2>
<p class="First">In a controlled double-blind study conducted in the US, moxifloxacin tablets (400 mg once daily for ten days) were compared with cefuroxime axetil (250 mg twice daily for ten days) for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.Â  The trial included 457 patients valid for the efficacy analysis.Â  Clinical success (cure plus improvement) at the 7 to 21 day post-therapy test of cure visit was 90% for moxifloxacin and 89% for cefuroxime. </p>
<br><p>An additional non-comparative study was conducted to gather bacteriological data and to evaluate microbiological eradication in adult patients treated with moxifloxacin 400 mg once daily for seven days.Â  All patients (n = 336) underwent antral puncture in this study.Â  Clinical success rates and eradication/presumed eradication rates at the 21 to 37 day follow-up visit were 97% (29 out of 30) for <span class="Italics">Streptococcus pneumoniae</span>, 83% (15 out of 18) for <span class="Italics">Moraxella catarrhalis</span>, and 80% (24 out of 30) for <span class="Italics">Haemophilus influenzae</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Uncomplicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">A randomized, double-blind, controlled clinical trial conducted in the US compared the efficacy of moxifloxacin 400 mg once daily for seven days with cephalexin HCl 500 mg three times daily for seven days.Â  The percentage of patients treated for uncomplicated <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> was 30%, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furuncles</span> 8%, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span> 16%, <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span> 20%, and other <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> 26%.Â  Adjunctive procedures (incision and drainage or debridement) were performed on 17% of the moxifloxacin-treated patients and 14% of the comparator treated patients.Â  Clinical success rates in evaluable patients were 89% (108/122) for moxifloxacin and 91% (110/121) for cephalexin HCl.Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Complicated Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Two randomized, active controlled trials of cSSSI were performed.Â  A double-blind trial was conducted primarily in North America to compare the efficacy of sequential IV/PO moxifloxacin 400 mg QD for 7 to 14 days to an IV/PO beta-lactam/beta-lactamase inhibitor control in the treatment of patients with cSSSI.Â  This study enrolled 617 patients, 335 of which were valid for the efficacy analysis.Â  A second open-label International study compared moxifloxacin 400 mg QD for 7 to 21 days to sequential IV/PO beta-lactam/beta-lactamase inhibitor control in the treatment of patients with cSSSI.Â  This study enrolled 804 patients, 632 of which were valid for the efficacy analysis.Â  Surgical incision and drainage or debridement was performed on 55% of the moxifloxacin-treated and 53% of the comparator treated patients in these studies and formed an integral part of therapy for this indication.Â  Success rates varied with the type of diagnosis ranging from 61% in patients with infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> to 90% in patients with complicated <span class="product-label-link" type="condition" conceptid="138346" conceptname="Erysipelas">erysipelas</span>.Â  These rates were similar to those seen with comparator drugs.Â  The overall success rates in the evaluable patients and the clinical success by pathogen are shown in Tables 13 and 14. </p>
<br><p><span class="Bold">Table 13: Overall Clinical Success Rates in Patients with Complicated </span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 36.9pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Study</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Moxifloxacin</span><br><span class="Bold">n/N (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">95% Confidence Interval*</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">North America <br>
</td>
<td class="Rrule" align="center" valign="top">125/162 (77.2%)<br>
</td>
<td class="Rrule" align="center" valign="top">141/173 (81.5%)<br>
</td>
<td class="Rrule" align="center" valign="top">(-14.4%, 2%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">International <br>
</td>
<td class="Rrule" align="center" valign="top">254/315 (80.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">268/317 (84.5%)<br>
</td>
<td class="Rrule" align="center" valign="top">(-9.4%, 2.2%)<br>
</td>
</tr>
</tbody></table>
<p>* of difference in success rates between moxifloxacin and comparator (moxifloxacin -Â comparator)<br>Â </p>
<br><p><span class="Bold">Table 14: Clinical Success Rates by Pathogen in Patients with Complicated </span></p>
<p><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 36.9pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Pathogen </span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Moxifloxacin</span><br><span class="Bold">n/N (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus </span><br>(methicillin-susceptible isolates)<span class="Sup">a</span><br>
</td>
<td class="Rrule" align="center" valign="top">106/129 (82.2%)<br>
</td>
<td class="Rrule" align="center" valign="top">120/137 (87.6%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Escherichia coli </span><br>
</td>
<td class="Rrule" align="center" valign="top">31/38 (81.6%)<br>
</td>
<td class="Rrule" align="center" valign="top">28/33 (84.8%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Klebsiella pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">11/12 (91.7%)<br>
</td>
<td class="Rrule" align="center" valign="top">7/10 (70%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterobacter cloacae </span><br>
</td>
<td class="Rrule" align="center" valign="top">9/11 (81.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">4/7 (57.1%)<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a </span>Â methicillin susceptibility was only determined in the North American StudyÂ Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.7"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></h2>
<p class="First">Two randomized, active controlled trials of cIAI were performed.Â  A double-blind trial was conducted primarily in North America to compare the efficacy of sequential IV/PO moxifloxacin 400 mg QD for 5 to 14 days to IV/piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI, including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> with perforation, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span>.Â  This study enrolled 681 patients, 379 of which were considered clinically evaluable.Â  A second open-label international study compared moxifloxacin 400 mg QD for 5 to 14 days to IV ceftriaxone plus IV metronidazole followed by PO amoxicillin/clavulanic acid in the treatment of patients with cIAI.Â  This study enrolled 595 patients, 511 of which were considered clinically evaluable.Â  The clinically evaluable population consisted of subjects with a surgically confirmed complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, at least 5 days of treatment and a 25 to 50 day follow-up assessment for patients at the Test of Cure visit.Â  The overall clinical success rates in the clinically evaluable patients are shown in Table 15. </p>
<br><p><span class="Bold">Table 15: Clinical Success Rates in Patients with Complicated Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></span></p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 40.8pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Study</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Moxifloxacin</span><br><span class="Bold">n/N (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Comparator</span><br><span class="Bold">n/N (%)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">95% Confidence Interval<span class="Sup">a</span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">North America (overall) <br>
</td>
<td class="Rrule" align="center" valign="top">146/183 (79.8%)<br>
</td>
<td class="Rrule" align="center" valign="top">153/196 (78.1%)<br>
</td>
<td class="Rrule" align="center" valign="top">(-7.4%, 9.3%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span> <br>
</td>
<td class="Rrule" align="center" valign="top">40/57 (70.2%)<br>
</td>
<td class="Rrule" align="center" valign="top">49/63 (77.8%)<span class="Sup">b</span><br>
</td>
<td class="Rrule" align="center" valign="top">NA<span class="Sup">c</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  Non-<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> <br>
</td>
<td class="Rrule" align="center" valign="top">106/126 (84.1%)<br>
</td>
<td class="Rrule" align="center" valign="top">104/133 (78.2%)<br>
</td>
<td class="Rrule" align="center" valign="top">NA<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">International (overall) <br>
</td>
<td class="Rrule" align="center" valign="top">199/246 (80.9%)<br>
</td>
<td class="Rrule" align="center" valign="top">218/265 (82.3%)<br>
</td>
<td class="Rrule" align="center" valign="top">(-8.9%, 4.2%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span> <br>
</td>
<td class="Rrule" align="center" valign="top">73/93 (78.5%)<br>
</td>
<td class="Rrule" align="center" valign="top">86/99 (86.9%)<br>
</td>
<td class="Rrule" align="center" valign="top">NA<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â  Non-<span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> <br>
</td>
<td class="Rrule" align="center" valign="top">126/153 (82.4%)<br>
</td>
<td class="Rrule" align="center" valign="top">132/166 (79.5%)<br>
</td>
<td class="Rrule" align="center" valign="top">NA<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a</span>Â of difference in success rates between moxifloxacin and comparator (moxifloxacin â€“ </p>
<p>Â  comparator)</p>
<p><span class="Sup">b</span> Excludes 2 patients who required additional surgery within the first 48 hours.</p>
<p><span class="Sup">c</span> NA â€“ not applicableÂ </p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<br><ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Tenth Edition</span>. CLSI document M07-A10 [2015], Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement</span>, CLSI document M100-S25Â  [2015], Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard â€“ Twelfth Edition</span>. CLSI document M02-A12 [2015], Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.</li>
<li>CLSI, <span class="Underline">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria</span> 8th edition; Approved Standard CLSI Document M11-A8, 2012.Â </li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold"><span class="Underline">How Supplied</span></span></p>
<p>Moxifloxacin Injection 400 mg/250 mL is a sterile solution available in a single-use, ready-to-use flexible plastic container. </p>
<br><p>No further dilution is necessary.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  </p>
<table border="0" cellpadding="0" cellspacing="0" width="margin: auto auto auto 45.9pt"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product </span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Â </span><br><span class="Bold">Strength</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Â </span><br><span class="Bold">Bag Size</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">850174<br>
</td>
<td class="Rrule" valign="top">63323-850-74<br>
</td>
<td class="Rrule" valign="top">400 mg per 250 mL<br>(1.6 mg per mL)<br>
</td>
<td class="Rrule" valign="top">300 mL <br>
</td>
</tr>
</tbody></table>
<p>Parenteral drug products should be inspected visually for particulate matter prior to administration.Â  Samples containing visible particulates should not be used. </p>
<p>Because the premix flexible plastic containers are for single-use only, any unused portion should be discarded. </p>
<br><p><span class="Bold"><span class="Underline">Storage and Handling</span></span></p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature]. </p>
<p><span class="Bold">Do not refrigerateÂ - Product precipitates upon refrigeration. </span></p>
<p><span class="Bold">Use immediately once removed from the overwrap.Â  Product is sensitive to light.</span></p>
<p>The container closure is not made with natural rubber latex, polyvinyl chloride (Non-PVC), or di-(2-ethylhexyl)phthalate (Non-DEHP).Â </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Medication Guide.</p>
<p><span class="Bold">Antibacterial Resistance </span></p>
<p>Antibacterial drugs including moxifloxacin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.Â  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (for example, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).Â  When moxifloxacin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.Â  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by moxifloxacin or other antibacterial drugs in the future.</p>
<p><span class="Bold">Serious and Potentially Serious Adverse Reactions </span></p>
<p>To assure safe and effective use of moxifloxacin, patients should be informed of the following serious adverse reactions that have been associated with moxifloxacin and other fluoroquinolone use: </p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">Tendon Disorders</span>:</span> Patients should contact their healthcare provider if they experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of a tendon, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or inability to use one of their joints; rest and refrain from exercise; and discontinue moxifloxacin treatment.Â  The risk of severe <span class="product-label-link" type="condition" conceptid="442264" conceptname="Disorder of tendon">tendon disorder</span> with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold">Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span>:</span> Fluoroquinolones like moxifloxacin may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems.Â  Patients should call their healthcare provider right away if they have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold">Prolongation of the QT interval:</span> Moxifloxacin may produce changes in the electrocardiogram (QTc interval prolongation).Â  Moxifloxacin should be avoided in patients receiving Class IA (for example quinidine, procainamide) or Class III (for example amiodarone, sotalol) antiarrhythmic agents.Â  Moxifloxacin may add to the QTc prolonging effects of other drugs such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants.Â  The patients should inform their physician of any personal or family history of QTc prolongation or proarrhythmic conditions such as recent <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">acute myocardial ischemia</span>.Â  Patients should contact their physician if they experience <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> spells while taking moxifloxacin. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> Patients should be advised that moxifloxacin may be associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, even following a single dose.Â  Patients should discontinue moxifloxacin at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or other signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported in patients receiving quinolones, and they should notify their physician before taking moxifloxacin if there is a history of this condition.Â  Patients should also inform their physician if they are taking NSAIDs concurrently with moxifloxacin. </li></ul>
<br><ul class="Disc"><li>
<span class="Bold">Neurologic Adverse Effects (for example, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>):</span>Â  Moxifloxacin may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and vision disorders therefore, patients should know how they react to this drug before they operate an automobile or machinery or engage inÂ  activities requiring mental alertness or coordination. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reaction</span>:</span> <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> sometimes resulting in self-injurious behavior have been reported in patients receiving quinolones.Â  Patients should notify their physician if they have a history of psychiatric illness before taking moxifloxacin. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold">Peripheral Neuropathies:</span> Patients should be informed that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> has been associated with moxifloxacin use.Â  Symptoms may occur soon after initiation of therapy and may be irreversible.Â  If symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, and/or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develop, patients should immediately discontinue moxifloxacin and contact their physician. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold">Blood Glucose Disturbances:</span> Inform the patients that if they are diabetic and are being treated with insulin or an oral hypoglycemic agent and a <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span> occurs, they should discontinue moxifloxacin and consult a physician. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Phototoxicity</span>:</span> Patients should be informed that <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>/<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> has been reported in patients receiving quinolones.Â  Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking quinolones.Â  If patients need to be outdoors while using quinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.Â  If a sunburn-like reaction or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruption</span> occurs, patients should contact their physician. </li></ul>
<br><br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.Â  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.Â  If this occurs, patients should contact their physician as soon as possible.</li></ul>
<p>The brand names mentioned in this document are the trademarks of their respective owners.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_18"></a><a name="section-17"></a><p></p>
<h1>SPL MEDGUIDE SECTION</h1>
<p class="First"><span class="Bold">Moxifloxacin Injection</span></p>
<p><span class="Bold">(mox i FLOX a sin) (in jekÂ´ shÅ­n)</span></p>
<p><span class="Bold">solution for intravenous use</span></p>
<p>Read the Medication Guide that comes with Moxifloxacin Injection<span class="Sup">Â </span>before you start receiving it and each time you receive it.Â  There may be new information.Â  This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about moxifloxacin injection? </span></p>
<p>Moxifloxacin injection belongs to a class of antibiotics called fluoroquinolones.Â  Moxifloxacin injection can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Â If you get any of the following serious side effects, get medical help right away.Â  Talk with your healthcare provider about whether you should continue to receive moxifloxacin injection. <br><span class="Bold">1.</span> Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tendon (<span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>). </span></p>
<p><span class="Bold">â€¢</span>Â Â Â Â Â  <span class="Bold">Tendon problems can happen in people of all ages who receive moxifloxacin injection.</span>Â  Tendons are tough cords of tissue that connect muscles to bones.Â  Symptoms of tendon problems may include:</p>
<ul class="Disc"><li><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, tears and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites. </li></ul></li></ul>
<p><span class="Bold">â€¢</span>Â Â Â Â  The risk of getting tendon problems while you receive moxifloxacin injection isÂ higher if you: </p>
<ul class="Disc"><li><ul class="Disc">
<li>Are over 60 years of age</li>
<li>Are taking steroids (corticosteroids) </li>
<li>Have had a kidney, heart or lung transplant </li>
</ul></li></ul>
<p><span class="Bold">Tendon problems can happen in people who do not have the above risk factors when they receive moxifloxacin injection. </span></p>
<ul class="Disc"><li>Other reasons that can increase your risk of tendon problems can include:    <ul class="Disc">
<li>Physical activity or exercise </li>
<li><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney failure</span></li>
<li>Tendon problems in the past, such as in people with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA). </li>
</ul>
</li></ul>
<ul class="Disc"><li><span class="Bold">Call your healthcare provider right away at the first sign of <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. </span></li></ul>
<p>Stop receiving moxifloxacin injection until <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span> or <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> has been ruled out by your healthcare provider.Â  Avoid exercise and using the affected area.Â  The most common area of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is in the Achilles tendon at the back of your ankle. Â This can also happen with other tendons. </p>
<ul class="Disc"><li><span class="Bold">Talk to your healthcare provider about the risk of <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span> with continued use of moxifloxacin injection.</span></li></ul>
<br><br><p>You may need a different antibiotic that is not a fluoroquinolone to treat your <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<ul class="Disc"><li><span class="Bold"><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span> can happen while you are taking or after you have finished receiving moxifloxacin injection.</span></li></ul>
<br><br><p><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon ruptures</span> have happened up to several months after patients have finished receiving their fluoroquinolone. </p>
<ul class="Disc"><li>
<span class="Bold">Get medical help right away if you get any of the following signs or symptoms of a <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>: </span><ul class="Disc">
<li>Hear or feel a snap or pop in a tendon area. </li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span> right after an injury in a tendon area. </li>
<li>Unable to move the affected area or bear weight. </li>
</ul>
</li></ul>
<p><span class="Bold">2.</span> Â <span class="Bold">Worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (a disease which causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>).</span></p>
<p>Fluoroquinolones like moxifloxacin injection may cause worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms, including <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and breathing problems.Â  Call your healthcare provider right away if you have any worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or breathing problems. </p>
<br><p>See the section <span class="Bold">â€œWhat are the possible side effects of moxifloxacin injection?â€?</span> for more information about side effects. </p>
<p><span class="Bold">What is moxifloxacin injection? </span></p>
<p>Moxifloxacin injection is a fluoroquinolone antibiotic medicine used to treat certain types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by certain germs called bacteria in adults 18 years or older.Â  It is not known if moxifloxacin injection is safe and works in people under 18 years of age.Â  Children have a higher chance of getting bone, joint, and tendon (musculoskeletal) problems while taking fluoroquinolone antibiotic medicines.Â Â </p>
<p>Sometimes <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are caused by viruses rather than by bacteria.Â  Examples include <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> in the sinuses and lungs, such as the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> or flu.Â  Antibiotics, including moxifloxacin injection, do not kill viruses.Â  Call your healthcare provider if you think your condition is not getting better while you are receiving moxifloxacin injection.</p>
<p><span class="Bold">Who should not receive moxifloxacin injection?</span></p>
<p>Do not receive moxifloxacin injection if you have ever had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to an antibiotic known as a fluoroquinolone, or if you are allergic to any of the ingredients in moxifloxacin injection.Â  Ask your healthcare provider if you are not sure.Â  See the list of ingredients in moxifloxacin injection at the end of this Medication Guide. </p>
<p><span class="Bold">What should I tell my healthcare provider before receiving moxifloxacin injection? </span></p>
<p><span class="Bold">See â€œWhat is the most important information I should know about moxifloxacin injection?â€? </span></p>
<p><span class="Bold">Tell your healthcare provider about all your medical conditions, including if you: </span></p>
<ul class="Disc">
<li>Have tendon problems </li>
<li>Have a disease that causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>) </li>
<li>Have central nervous system problems (such as <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>) </li>
<li>Have nerve problems </li>
<li>Have or anyone in your family has an irregular heartbeat, especially a condition called â€œQT prolongationâ€?</li>
<li>Have low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) </li>
<li>Have a slow heartbeat (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>) </li>
<li>Have <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span></li>
<li>Have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </li>
<li>Have kidney problems </li>
<li>Have <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) or other history of joint problems </li>
<li>Are on a salt-restricted diet</li>
<li>Have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or problems with low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</li>
<li>Are pregnant or planning to become pregnant.Â  It is not known if moxifloxacin injection will harm your unborn child. </li>
<li>Are breastfeeding or planning to breastfeed.Â  It is not known if moxifloxacin injection passes into breast milk. Â You and your healthcare provider should decide whether you will receive moxifloxacin injection or breastfeed. </li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal and dietary supplements.Â  Moxifloxacin injection and other medicines can affect each other causing side effects.Â  Especially tell your healthcare provider if you take: </p>
<ul class="Disc">
<li>An NSAID (Non-Steroidal Anti-Inflammatory Drug).Â  Many common medicines for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief are NSAIDs.Â  Taking an NSAID while you receive moxifloxacin injection or other fluoroquinolones may increase your risk of central nervous system effects and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. </li>
<li>A blood thinner (warfarin, Coumadin, Jantoven). </li>
<li>A medicine to control your heart rate or rhythm (antiarrhythmic).Â  See <span class="Bold">â€œWhat are the possible side effects of moxifloxacin injection?â€?</span>
</li>
<li>An anti-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> medicine. </li>
<li>A tricyclic antidepressant. </li>
<li>An oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine or insulin.</li>
<li>Erythromycin. </li>
<li>A water pill (diuretic). </li>
<li>A steroid medicine.Â  Corticosteroids taken by mouth or by injection may increase the chance of <span class="product-label-link" type="condition" conceptid="4344040" conceptname="Tendon injury">tendon injury</span>. Â See <span class="Bold">â€œWhat is the most important information I should know about moxifloxacin injection?â€?</span>
</li>
</ul>
<p><span class="Bold">Ask your healthcare provider if you are not sure if any of your medicines are listed above. </span></p>
<p>Know the medicines you take. Â Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I receive moxifloxacin injection? </span></p>
<ul class="Disc">
<li>Moxifloxacin injection is given to you by intravenous (IV) infusion into your vein slowly, over 60 minutes, as prescribed by your healthcare provider. </li>
<li>
<span class="Bold">Do not</span> skip any doses, or stop receiving moxifloxacin injection even if you begin to feel better, until you finish your prescribed treatment, unless:    <ul class="Disc">
<li>You have tendon effects (see â€œWhat is the most important information I should know about moxifloxacin injection?â€?). </li>
<li>You have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (see â€œWhat are the possible side effects of moxifloxacin injection?â€?), or your healthcare provider tells you to stop. Â </li>
</ul>
</li>
</ul>
<p>This will help make sure that all of the bacteria are killed and lower the chance that the bacteria will become resistant to moxifloxacin injection.Â  If this happens, moxifloxacin injection and other antibiotic medicines may not work in the future. Â </p>
<p><span class="Bold">What should I avoid while receiving moxifloxacin injection? </span></p>
<ul class="Disc">
<li>Moxifloxacin injection can make you feel dizzy and lightheaded.Â  <span class="Bold">Do not</span> drive, operate machinery, or do other activities that require mental alertness or coordination until you know how moxifloxacin injection affects you. </li>
<li>Avoid sunlamps, tanning beds, and try to limit your time in the sun.Â  Moxifloxacin injection can make your skin sensitive to the sun (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>) and the light from sunlamps and tanning beds. </li>
<li>You could get severe sunburn, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your skin.Â  If you get any of these symptoms while receiving moxifloxacin injection, call your healthcare provider right away.Â  You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. </li>
</ul>
<p><span class="Bold">What are the possible side effects of moxifloxacin injection? </span></p>
<p><span class="Bold">Moxifloxacin injection can cause side effects that may be serious or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span>Â  See <span class="Bold">â€œWhat is the most important information I should know about moxifloxacin injection?â€?</span> Â </p>
<p>Other serious side effects of moxifloxacin injection include: </p>
<br><br><ul class="Disc">
<li>
<span class="Bold">Serious heart rhythm changes (QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>).Â  </span>Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.Â  Moxifloxacin injection may cause a rare heart problem known as prolongation of the QT interval.Â  This condition can cause an abnormal heartbeat and can be very dangerous.Â  The chances of this event are higher in people:    <ul class="Disc">
<li>Who are elderly </li>
<li>With a family history of prolonged QT interval </li>
<li>With low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>)</li>
<li>Who take certain medicines to control heart rhythm (antiarrhythmics)Â </li>
</ul>
</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.Â  </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> can happen in people taking fluoroquinolones, including moxifloxacin injection, even after only 1 dose.Â  Stop receiving moxifloxacin injection and get emergency medical help right away if you get any of the following symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>: </li>
</ul>
<ul class="Disc">
<li><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></li>
<li>Trouble breathing or swallowing</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span></li>
<li>Rapid heartbeat</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Faint</span></li>
<li>Yellowing of the skin or eyes.Â  Stop receiving moxifloxacin injection and tell your healthcare provider right away if you get yellowing of your skin or white part of your eyes, or if you have dark urine.Â  These can be signs of a serious reaction to moxifloxacin injection (a liver problem).</li>
</ul></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>.Â  </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may happen in people receiving moxifloxacin injection even after only 1 dose.Â  Stop receiving moxifloxacin injection at the first sign of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and call your healthcare provider.Â  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> may be a sign of a more serious reaction to moxifloxacin injection.</li>
<li>
<span class="Bold">Central Nervous System effects. Â </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in people who take fluoroquinolone antibiotics including moxifloxacin injection.Â  Tell your healthcare provider if you have a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.Â  Ask your healthcare provider whether receiving moxifloxacin injection will change your risk of having a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.Â Â Â </li>
</ul>
<p>Central Nervous System (CNS) side effects may happen as soon as after receiving the first dose of moxifloxacin injection.Â  Talk to your healthcare provider right away if you have any of these side effects, or other changes in mood or behavior: </p>
<ul class="Disc">
<li>Feeling dizzy </li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </li>
<li>Hear voices, see things, or sense things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>) </li>
<li>Feel <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> </li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span> </li>
<li>Feel anxious or nervousÂ Â </li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> </li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </li>
<li>Trouble sleeping </li>
<li>Feel more suspicious (<span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>) </li>
<li>Suicidal thoughts or acts </li>
<li><span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmares</span> </li>
<li>Vision LossÂ </li>
</ul>
<ul class="Disc">
<li>
<span class="Bold">Intestine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span>).</span> Â <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen with most antibiotics, including moxifloxacin injection.Â  Call your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>.Â  You may have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.Â  <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen 2 or more months after you have finished your antibiotic. </li>
<li>
<span class="Bold">Changes in sensation and <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>). Â </span>Damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including moxifloxacin injection.Â  Stop moxifloxacin injection and talk with your healthcare provider right away if you get any of the following symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> in your arms, hands, legs, or feet:    <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </li>
<li>Burning </li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> </li>
</ul>
</li>
</ul>
<p>The <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> may be permanent. </p>
<ul class="Disc">
<li>
<span class="Bold">Changes in blood sodium.Â  </span>Increased blood sodium can happen in people who receive moxifloxacin injection. Â Tell your healthcare provider if you are on a salt-restricted diet or have <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Â Your antibiotic medicine may need to be changed. </li>
<li>
<span class="Bold">Changes in blood sugar.</span> Â People who receive moxifloxacin injection and other fluoroquinolone medicines with oral anti-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines or with insulin can get low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>).Â  Follow your healthcare provider's instructions for how often to check your blood sugar.Â  If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and you get low blood sugar while receiving moxifloxacin injection, stop receiving moxifloxacin injection and call your healthcare provider right away.Â  Your antibiotic medicine may need to be changed.</li>
<li><span class="Bold">Sensitivity to sunlight (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>).</span></li>
</ul>
<p>Â  See â€œWhat should I avoid while receiving moxifloxacin injection?â€?Â  </p>
<p>The most common side effects of moxifloxacin injection include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li>DizzinessÂ  </li>
</ul>
<p>These are not all the possible side effects of moxifloxacin injection.Â  Tell your healthcare provider about any side effect that bothers you or that does not go away.Â  Call your doctor for medical advice about side effects.Â  You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store moxifloxacin injection?</span></p>
<ul class="Disc">
<li>Store moxifloxacin injection at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</li>
<li>Keep the moxifloxacin injection bag in the outer bag and out of the light until you are ready to use it. Â Moxifloxacin injection should be used right away after removing it from the outer bag. </li>
<li>
<span class="Bold">Do not</span> refrigerate.</li>
<li>Moxifloxacin injection is for single use only. </li>
<li>Keep moxifloxacin injection and all medicines out of the reach of children. </li>
</ul>
<p><span class="Bold">General Information about the safe and effective use of moxifloxacin injection.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.Â  Do not use moxifloxacin injection for a condition for which it is not prescribed.Â  Do not give moxifloxacin injection to other people, even if they have the same symptoms that you have.Â  It may harm them. </p>
<br><p>This Medication Guide summarizes the most important information about moxifloxacin injection.Â  If you would like more information about moxifloxacin injection, talk with your healthcare provider.Â  You can ask your healthcare provider or pharmacist for information about moxifloxacin injection that is written for healthcare professionals.Â  For more information call 1-800-551-7176. </p>
<p><span class="Bold">What are the ingredients in moxifloxacin injection?</span></p>
<p><span class="Bold">Active ingredient:</span> moxifloxacinÂ Â </p>
<p><span class="Bold">Inactive ingredients:</span> sodium acetate-trihydrate, disodium sulfate, sulfuric acid (for pH adjustment), and water for injection</p>
<br><p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<br><p>Manufactured for:</p>
<br><br><div class="Figure"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4e28b09-714b-46e7-b4e6-0163cad78fc5&amp;name=fk-address.jpg"></div>
<br><p>Made in Norway<br>451325B<br>Revised: April 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold"><br><br>PACKAGE LABEL - PRINCIPAL DISPLAY - Moxifloxacin 250 mL Bag Label</span></p>
<p><span class="Bold">NDC</span> 63323-850-74</p>
<p>850174</p>
<p><span class="Bold">Moxifloxacin Injection</span></p>
<p><span class="Bold">400 mg* per 250 mLÂ  (1.6 mg per mL)Â Â  <br></span>For Intravenous InfusionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Rx only</p>
<p>Use immediately once removed from the overwrap.</p>
<p>Infuse over 60 minutes.<br><br><br><br><img alt="bag" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4e28b09-714b-46e7-b4e6-0163cad78fc5&amp;name=bag-850174.jpg"></p>
<br><br><br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOXIFLOXACINÂ 		
					</strong><br><span class="contentTableReg">moxifloxacin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-850</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MOXIFLOXACIN HYDROCHLORIDE</strong> (MOXIFLOXACIN) </td>
<td class="formItem">MOXIFLOXACIN</td>
<td class="formItem">400Â mg Â inÂ 250Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-850-74</td>
<td class="formItem">250 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205572</td>
<td class="formItem">03/18/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi Norge AS</td>
<td class="formItem"></td>
<td class="formItem">731170932</td>
<td class="formItem">MANUFACTURE(63323-850)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ee0db6d7-4c75-4ac2-a552-5a124547295b</div>
<div>Set id: a4e28b09-714b-46e7-b4e6-0163cad78fc5</div>
<div>Version: 1</div>
<div>Effective Time: 20150416</div>
</div>
</div>Â <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
